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HIV epidemic is an ongoing health concern globally. Sexual transmission accounts for 
the overwhelming majority of new infections. Vaginal microbicides are under investigation as 
pre-exposure prophylaxis (PrEP) products for HIV prevention. Although progress has been 
made, the development of more efficacious products is warranted. Cervicovaginal tissue and 
draining lymph nodes contain an adequate amount of HIV target cells and play critical roles in 
HIV replication and sedimentation at the early stage of infection. Improved efficacy can be 
achieved with the use of specially designed drug delivery systems which achieve greater drug 
concentrations in these two sites of action.  
In this dissertation, we hypothesized that the hydrophobic microbicide candidate CSIC 
can be formulated in a polymeric vaginal film and a nanocrystal formulation with high loading 
capacities using multiple formulation strategies. We further hypothesized that the nano-delivery 
strategy can improve cervicovaginal tissue drug penetration and achieve lymphatic drug delivery. 
Series of preformulation studies were conducted to evaluate the physicochemical and biological 
properties of the drug candidate CSIC.  The major challenge for CISC formulation development 
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was identified as its hydrophobicity. Therefore, a cosolvent system comprising PEG 400, 
propylene glycol, and glycerin at a ratio of 5:2:1 has been optimized and utilized in a polymer 
based vaginal film formulation for increased drug solubility, long term stability, and lack of 
leakage. Additionally, a CSIC nanocrystal formulation, with a particle size of 243nm and near 
neutral surface charge, was developed. CSIC nanocrystals have been proved to possess increased 
drug saturation solubility, rapid mucus penetration properties, and improved drug permeation in 
the cervicovaginal tissue. More importantly, the pharmacokinetic study provided the first 
evidence of lymphatic targeting after intravaginal application without causing any epithelial 
damage. Furthermore, CSIC was able to release from the nanocrystals in a sustained mode, 
indicating its potential use as a coitally independent PrEP product that could improve user 
adherence. In summary, this work sets the stage to create new opportunities for sexually 
transmitted HIV prevention through the development of a novel dual targeting delivery system. 
The developed approaches can be used to deliver other drugs that lack solubility or require 
lymphatic targeting.  
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1.0  INTRODUCTION AND SPECIFIC AIMS 
1.1 HIV -1 FEMALE SEXUAL TRANSMISSION  
1.1.1 HIV/AIDS epidemic 
Human immunodeficiency virus (HIV) infection has spread rapidly around the world following 
the earliest reported cases of Acquired Immunodeficiency Syndrome (AIDS) in the 1980s. Since 
that time the AIDS epidemic has become a major global public health issue. In 2013, 2.1 million 
people were newly infected by HIV, and 1.5 million people died from AIDS-related diseases. 
Despite the declining numbers of new HIV infections and AIDS related deaths in the past 
decade, the epidemic is still alarming. By the end of 2013, approximately 35 million people were 
living with HIV[1]. Among all the HIV positive people eligible for HIV treatment under the 
2013 World Health Organization guidelines, only 34% (9.7 million) received antiretroviral 
therapy. Reasons for this extreme lack of treatment include the unawareness of infection, 
poverty, and HIV related stigma and discrimination. The existence of this large untreated 
population arouses a great social panic as they increase the risk of HIV transmission.  
In addition to the antiretroviral drug treatment, prevention is critical to protect people at 
risk from HIV acquisition, thus curbing the growth of the HIV/AIDS epidemic. Preventative 
strategies including condom use, male circumcision, reduction in number of sexual partners, and 
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less risky sex have drawn a great amount of attention in the past decades. Among other options, a 
new approach called Pre-Exposure Prophylaxis (PrEP) has been approved by FDA to prevent 
HIV infection. The target population for PrEP intervention is the HIV negative and at substantial 
risk of getting infection. To date, Truvada is the only drug product that has been approved for the 
purpose of oral PrEP.  It is a combination of the nucleotide reverse transcriptase inhibitor 
(NtRTI) tenofovir (TFV) and the nonnucleoside reserve transcriptase inhibitor (NNRTI) 
emtricitabine. Other than oral PrEP, substantial efforts have been made towards the development 
of injectable PrEP and topical PrEP. Currently, the HIV Prevention Trials Network (HPTN) has 
launched two phase II clinical studies, HPTN 076 and HPTN 077, which are designed to 
evaluate the safety and acceptability of long-acting injectable antiretroviral drugs. These 
injectable products are very promising since they can stay in the body for several months and 
protect people at risk of HIV infection. Topical PrEP refers to the category of products 
administrated vaginally or rectally. Success has been achieved in topical PrEP studies such as the 
TFV 1% vaginal gel and dapivirine (NNRTI) vaginal ring. Both products are under investigation 
in Phase III clinical studies for efficacy [2-4]. Despite the progress that has been made, the 
development of more efficacious products is warranted. Improved efficacy can be achieved with 
the use of specially designed drug delivery systems which achieve greater drug concentrations 
where needed. 
 
1.1.1 Physiological factors related to HIV infections in women 
Women account for 52% of HIV positive people in the low-and middle –income 
countries. In sub-Saharan Africa,  76% of the  infected population in the 15-24 age group are 
female [5]. The overwhelming majority of the new infections in women (84% in 2010) were 
 3 
caused by heterosexual contacts [6]. Numerous reasons account for the high vulnerability of 
women, including physiological factors, gender disparities, sexual norms, violence, poverty, and 
limited access to education [7]. Physiologically, women are more susceptible to HIV acquisition 
than their male partners. The male to female HIV transmission rate is approximately two times as 
likely compared to the female to male transmission during vaginal intercourse [8]. The increased 
susceptibility is associated with the use of hormonal contraceptives, ovulation, and pregnancy [1, 
9-12].  It is well known that the immune system in the female reproductive tract is mainly 
regulated by sexual hormones such as estradiol, progesterone, luteinizing hormone, and the 
follicle-stimulating hormone. When sexual hormones suppress the innate, humoral, or cell-
mediated immune systems, viral infectivity in the female reproductive tract will be enhanced. In 
addition, previous investigations have shown that both ulcerative and non-ulcerative sexually 
transmitted diseases (STDs) also facilitate HIV transmission by boosting HIV infectiousness and 
susceptibility [13]. The promoted HIV infectiousness is achieved by increased HIV shedding and 
genital bleeding in the genital tract. Meanwhile, the presence of other STDs increases human 
susceptibility to the virus by recruiting a large number of HIV target inflammatory cells to the 
site of infection and inducing mucosal disruption.  
 
1.1.2 Early events of HIV-1 infection in the female reproductive tract 
Previous studies, using a rhesus macaque nonhuman primate model, have shown that once the 
macaque’s vagina was exposed to simian immunodeficiency virus (SIV), the virus penetrated 
through the mucosal epithelia within hours (Figure 1) [14]. The potential mechanisms for viral 
entry include direct epithelial infection, transcytosis, transmigration, internalization by 
 4 
Langerhans cells, and the micro-trauma caused by sexual intercourse [15, 16]. The sites of viral 
entry are likely to be the endocervix and the transformation zone between the endo- and 
ectocervix since the epithelium in these two areas consists of a single layer epithelial cells in 
contrast to the multilayered vaginal epithelium. During the first week of infection, HIV mainly 
infects “resting” CD4 T cells in the cervicovaginal tissue [17]. These specific CD4 T cells do not 
express markers of activation on their surface but express some residue of co-receptors which 
facilitate viral replication and subsequent infection and work as a latent reservoir [18]. Other 
than the “resting” CD4 T cells, HIV also infects activated CD4 T cells, Langerhans cells, and 
macrophages [19]. The cells that are infected first, called the founder population, expand in the 
local tissue and are disseminated to the draining lymph nodes rapidly. During the second week, 
the self- propagating systemic infection is established in the secondary lymphoid organs such as 
the thoracic duct, spleen, lymph nodes, and Peyer’s patches. After 4 weeks of HIV exposure, 
these infected lymphatic organs function as reservoirs for viral storage and production. In this 
regard, the most desirable window for HIV prevention would be the first week after HIV 
exposure as the infected founder populations are small and focal, and the self-propagating 
infection has not yet been established systemically.  
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Figure 1 Early events in vaginal transmission of simian immunodeficiency virus.  
Virus can penetrate in the cervicovaginal tissue within hours and infect a small group of susceptible 
target cells, founder population. The infected founder population expands locally and disseminated 
to the draining lymph nodes in the subsequent days. After the week 1, systemic infection will be 
established. The window for prevention is mainly in the stages of crossing the barriers, founder 
population and local expansion.  
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1.2 VAGINAL DRUG DELIVERY  
1.2.1 Anatomy and physiology of vagina 
The human vagina is a tubular and fibromuscular organ extending from vaginal vestibule to the 
cervix. The vagina is not a straight tube. When a woman is in a standing position, the axis of the 
lower vagina is more vertical and posterior, while the upper vagina from the pelvic diaphragm to 
the cervix curves horizontally forming a 130° angle [20]. This anatomical character provides the 
possibility for pharmaceutical products to stay in the vagina against gravitational forces.  
Based on histological examination, the vagina is composed of four layers: stratified 
squamous epithelium, lamina propria, a muscular layer, and the tunica adventitia. The surface of 
the vagina is covered by a series of transverse muscular folds called “rugae” which dramatically 
increase the surface area of vagina [21]. The thickness of the epithelial cells varies during the 
different phases of menstrual cycle. The blood supply of vagina is received from a plexus of 
arteries including the internal iliac artery, uterine, middle rectal, and internal pudendal arteries. 
Afterward, blood enters the peripheral circulation through the surrounding venous plexus, and 
eventually drains to the internal iliac vein, avoiding the hepatic metabolism. Small blood and 
lymphatic vessels exist only in the lamina propria and the underneath muscular layer but not in 
the squamous epithelium [22, 23].   
The human vagina is covered by a watery secretion called vaginal fluid. About 90% of 
the vaginal fluid is water, while salts, residual urine, cervical mucus, enzymes, enzyme 
inhibitors, lymphocytes, albumins, fatty acids, and epithelial debris account for the remaining 
10% [21]. The volume of vaginal fluid secreted varies from 0.5 mL to 10 mL per day depending 
on blood flow, age, menstrual cycle, and presence of sexual intercourse [24]. In addition, the 
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amount and the physicochemical properties of the mucus will change with the menstrual cycle, 
which in turn will have significant effects on the viscosity and flow elasticity of the vaginal 
fluids [23]. Taken together, all these variations will substantially affect drug adhesion in the 
vaginal lumen, diffusion though the mucus barriers, and the extent of absorption.  
Vaginal fluid is acidic with a pH about 3.5-4.5 [25]. The acidity is generated and 
maintained mainly by the commensal microorganism Lactobacillus. These bacteria convert the 
glycogen, synthesized by epithelial cells, to lactic acid which reduce the pH of the vaginal fluid 
[26]. The pH value changes during the menstrual cycle with the lowest pH detected during 
ovulation [27]. Some other physiological factors may also change the pH, such as the presence of 
semen (pH7.2-8.0), bacterial infections (pH 5.0-6.5), and menopause (6.0-7.5) [28].  Thus, a safe 
vaginal product must not affect the normal microflora and low pH milieu as they are essential for 
a healthy vaginal environment.  
 
1.2.2 General features of vaginal drug delivery 
Vaginal drug delivery has been commonly used in female-specific treatments. Because of its 
anatomical and physiological challenges, it is imperative to understand the advantages and 
limitations of this route of drug administration. Firstly, compared with oral administration, 
delivering drugs vaginally can avoid gastrointestinal (GI) absorption, the hepatic first pass 
metabolism and GI tract related side effects [29]. In addition, as the enzymatic category and 
activity in the vagina are different from that of GI tract, the vagina may be a favorable alternative 
site for the delivery of drugs that are susceptible for hepatic metabolism, especially proteins and 
peptides [21]. Given these factors decreases in drug dosing levels may achieve the same 
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biological effects. This may avoid some of the toxicities or side effects associated with higher 
dosing levels. Moreover, for the drugs that act topically in the vagina, intravaginal drug 
administration results in much higher drug concentrations in the reproductive tract tissues when 
compared to systemic administration, which in turn would lead to improved efficacy, especially 
for the antiretroviral drugs used as topical HIV prevention products. Additionally, it is important 
to note that vaginal delivery is not only a site for local acting drugs but also a  potential route for 
systemic adsorption due to the large surface area and rich blood supply of the vagina [30]. These 
physiological  characteristics allow for high drug permeation and bioavailability [31].  
Vaginal drug delivery, however, has a few limitations. The major issue concerning this 
route of administration is its poor and variable drug absorption. Vaginal physiological factors, 
such as epithelial thickness, fluid volume and composition, presence of cervical mucus, and 
vaginal pH have significant effects on the rate and extent of drug absorption. Furthermore, the 
stages of the menstrual cycle, pregnancy, menopause, age, sexual activity, and hydrophobicity of 
the drugs can also change drug absorption profiles [21, 31]. In addition, vaginal products are 
commonly reported as having a low retention time in the lumen due to the shedding of fluids and 
epithelium in the vagina. Furthermore, some products have been associated with poor 
spreadability or messiness. These limitations need to be overcome in order to achieve efficacy 
and user adherence.  
Taken as a whole, an ideal vaginal product should possess the following characteristics: 
(1) maintenance of the acidic microenvironment and the normal microbial flora in the female 
reproductive tract; (2) safe for vaginal use without causing irritation; (3) not likely to leak or 
become messy; (4) portable and allow for self-insertion; and (5) intercourse independent with no 
effects on sexual intercourses [29]. Additionally, it is worth noting that many factors, such as the 
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preference of the individuals and their partners, cultural norms, economic and sexual status, and 
age can affect women’s choice on vaginal products. Since the decision to use vaginal products is 
very personal, multiple product types may be required in order to meet the needs of all women 
and improve user acceptability and adherence.  
 
1.2.3 Vaginal delivery of PrEP agents for HIV-1 prevention 
As the vagina is the initial site of HIV infection during male to female transmission, it would be 
beneficial to dose PrEP agents topically in vagina, which will allow for a higher drug 
concentration in the cervicovaginal tissue relative to the oral dosing. Previous clinical studies 
have shown that after intravaginal application of TFV 1% gel, drug concentrations in the vagina 
were substantially (~1000-fold) higher than that after oral Truvada dosing [32]. More 
importantly, the anti-HIV efficacy is directly associated with drug concentration in the vaginal 
tissue. When the concentration of TFV diphosphate, the active metabolites of TFV, was higher 
than 1000 ng/mL, HIV incidence rate was significantly lower than the placebo group and the 
group with lower drug concentrations in tissue [32]. A similar finding was described in a 
randomized pharmacokinetic cross-over study [33]. Compared to oral dosing, vaginal delivery of 
the anti-retroviral drug TFV increased drug concentrations in the cervicovaginal tissue and 
reached a greater PrEP efficacy. Meanwhile, a lower serum concentration was observed after 
vaginal administration, which would help to avoid many systemic side effects related to the drug 
use.  
From the perspective of dosage form, vaginal applied microbicide products can be 
prepared as gels, creams, tablets, films, and rings. The gel dosage form was first chosen for 
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microbicide development since the drug candidates identified early in the field were themselves 
gel forming polymers [34]. Gel products are able to adhere to the surface of the vagina for a 
reasonable period of time before being removed. In addition, they are inexpensive and easy to 
make as well as familiar to women since many marketed vaginal products and lubricants are 
gels. However, several limitations related to the applications of gel dosage form should be 
considered [35]. The first concern is the stability issue associated with drugs that are unstable in 
water.  Generally aqueous based hydrogels are used vaginally. These products contain a large 
volume of water so they would not be compatible with water liable drugs. In this scenario, solid 
dosage forms which contain minimal to no water would be highly recommended. Furthermore, 
the cost for packaging of gel products can be high due to the need for applicators. This may 
make such products costs prohibitive for use in developing counties. More importantly, gel 
leakage after vaginal application has been reported which may negatively impact patient 
adherence. As a consequence,  solid dosage forms such as polymeric vaginal films have recently 
received increasing attention as alternatives for the vaginal application of antiretroviral drugs 
[36, 37]. Film products can be applied intravaginally without an applicator and dissolve rapidly 
in the vaginal fluid upon insertion. Because the amount of residual water in film formulations is 
very low, active pharmaceutical ingredients, especially the ones that are susceptible to 
degradation in aqueous medium, can be preserved well in this dosage form, and the drugs are 
less likely to leak [34, 38].  
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1.2.4 The use of nanotechnology for improved vaginal drug delivery  
Recently, nanoparticle based formulations such as liposomes, nanoemulsions, micelles, 
dendrimers, and polymeric nanoparticles have been investigated for the vaginal drug delivery of 
PrEP agents [39-44]. Nanoparticles can help increase drug solubility, provide sustained drug 
release, and achieve rapid mucus penetration. Presently, over 40% of the new drugs identified 
through combinational screening programs exhibit poor water solubility. Similarly, in the field of 
topical PrEP, a substantial number of lead candidates being evaluated in the clinical pipelines are 
highly hydrophobic, especially the NNRTIs [45-47]. Poor drug solubility causes many issues: (1) 
uncontrolled drug precipitation after administration and poor ability for drug  removal from the 
body during elimination, (2) use of excessive amounts of excipients or extreme pH conditions to 
enhance solubility, which may introduce toxicity concerns, (3) slow dissolution rate (dM/dt) due 
to the low drug concentration on the surface of the drug particles (Cs) as per the modified Noyes 
Whitney’s dissolution equation described in the Equation 1, (4) limited and erratic bioavailability 
as a result of drug loss and poor absorption, and (5) lack of dose-response correlation resulting in 
a suboptimal dosing regimen [48]. Therefore, well designed pharmaceutical formulation 
approaches must be pursued to improve drug solubility.  
                                                                      (Equation 1)                      
Where, 
M: mass of dissolved drug;   t: time;    dM/dt: dissolution rate 
A: surface area of the dissolving drug particles 
D: diffusion coefficient 
h: thickness of the boundary layer of the dissolution medium at the surface of the dissolving drug particles 
Cs: drug concentration on the surface of the drug particles 
Cb: drug concentration in the bulk of the dissolution medium 
(Cs-Cb): concentration gradient 
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Conventionally, many approaches have been applied to improve the solubility of 
hydrophobic drugs. The first is drug ionization by salt formation and pH adjustment [49, 50]. 
This method is most effective for acidic and basic drugs since ionization is easy to achieve and 
ionized products present higher aqueous solubility compared with neutral ones. However, as the 
ionized products are usually synthesized and isolated from organic solvents, they may be 
chemically unstable in aqueous environments and be converted to their original acid or base 
forms. As a consequence, the application of salt formation technology has been generally limited 
[49]. Another pharmaceutical approach to increase drug solubility is to use cosolvents such as 
propylene glycol, ethanol, and cremophor EL [51-53]. Cosolvents help to dissolve a sufficient 
amount of drugs. However, caution must be placed in the process of formulation development 
and clinical evaluation as excess amount of cosolvents could cause serious toxicities. 
Additionally, cyclodextrins and their derivatives have been applied to encapsulate hydrophobic 
drugs in order to improve drug solubility [54, 55]. Cyclodextrins are a group of molecules 
composed of sugar units. These sugar units are arranged in a circle and exist in a toroid shape 
with the hydroxyl groups protruding out. Due to this unique structure, the interior of 
cyclodextrins are more hydrophobic than the exterior so that hydrophobic drugs can be 
encapsulated to from inclusion complexes. This drug delivery system has been extensively 
investigated in the pharmaceutical field to formulate hydrophobic drug substances.  
Recently, nanotechnologies have been commonly used to increase the solubility of poorly 
water soluble drugs [56, 57]. As per Ostwald-Freundlich equation (Equation 2), decreasing 
particle radius (γ) can increase saturation solubility of drug particles (S). The increased saturation 
solubility will result in a higher amount of dissolved drug, and lead to an improved 
bioavailability. This affect is substantial for particles below 1 µm, especially those under 200nm. 
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                                                                                (Equation 2)                                                                       
Where, 
S: solubility of fine drug particle at temperature T 
S0: solubility of infinitely large particles (if r=∞) 
v: molar volume 
ϒ: interfacial surface tension of the solid  
r: radius of the fine particle 
R: gas constant 
T: temperature 
 
 
In addition to improved drug solubility, nano-formulations can be applied as a controlled 
release device to achieve sustained drug concentrations in local cervicovaginal tissue. A 
thermosensitive vaginal gel containing PLGA nanoparticles has been formulated to deliver 
antiretroviral drugs raltegravir and efavirenz for HIV prevention [58]. Sustained drug 
concentrations in HeLa cells could be detected for two weeks after the nanoparticle treatment. 
Similarly, antibiotic loaded liposome gels have been prepared to treat bacterial vaginosis [59, 
60]. In vitro release studies showed that approximately 30-50% of the drugs were retained in the 
gels after 24h. The ability of these systems to release actives in a sustained profile may allow for 
the development of coitally independent products, which have the potential to help increase user 
adherence and product efficacy.  
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Moreover, mucus penetrating properties can be achieved through modulation of 
nanoparticle size and surface charge. This property is of paramount importance for HIV 
prevention since the viscous cervicovaginal mucus can have a significant impact on the drug 
penetration, distribution, and elimination after vaginal administration [61, 62]. Rapid mucus 
penetration will reduce the amount of drug loss during mucus turnover and result in increased 
drug accumulation in the cervicovaginal tissue. 
 
1.3 LYMPHATIC TARGETING  
1.3.1 Anatomy and physiology of the lymphatic system in female reproductive tract  
The lymphatic system is composed of lymph, lymphatic capillaries/vessels, and lymphatic 
organs including lymph nodes, spleen and thymus. As a unique system parallelized to the 
cardiovascular system, it plays important physiological roles. Firstly, the lymphatic system helps 
maintain protein and fluid balance in the body. Vital plasma proteins existing in the interstitial 
fluid are collected in the lymphatic vessels and returned to the blood circulation. Excess fluid can 
also be drained from the interstitial spaces, and most of the fluid will be recycled. Meanwhile, 
the lymphatic system removes the dead cells, waste, debris, and toxins from the body before the 
lymph is returned to the blood. In the case of infection, lymphatic capillaries which are scattered 
throughout the tissue will collect antigens or antigen presenting cells in the interstitium and 
transport them to the draining lymph nodes. Afterwards, immune responses will be initiated via 
B cell and T cell priming. Moreover, the lymphatics also absorb lipids and fat-soluble vitamins 
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from the digestive system and subsequently transport these nutrients to the cells where they are 
needed.  
In the female reproductive tract, the lymphatic drainage system is widely distributed in 
the pelvic area. The lower third of the vagina drains to the common iliac, superficial inguinal, 
and perirectal nodes, the middle third drains to the common and internal iliac node, and the upper 
third drains to the external iliac nodes [31]. In the cervix, lymph drains to the external or internal 
iliac and sacral nodes.  
The mucosal immune system in the lower reproductive tract consists of a resident 
population of dendritic cells (DCs), macrophages, T cells, and B cells. In the vagina, the cell 
concentration of T cells is higher than the immature DCs, natural killer cells, and macrophages 
[63, 64]. CD8
+
 T cells accounted for over 60% of the total T cells in the lamina propria, while a 
much smaller number of CD4
+
 T cells were found [65]. In the cervix, cell availability in the 
endocervix is found to be significantly different from that in the ectocervix [66]. T cells and B 
cells are more prevalent in the ectocervix than the endocervix [63]. In the upper reproductive 
tract, mast cells and macrophages are the main subtypes of immune cells residing in the 
endometrium, while T cells only account for a small part of the population [67]. The density of 
leukocytes in the endometrial tissue is found to be the highest of the whole reproductive tract. In 
the fallopian tube, T cells are the major cell type among the leukocytes. Granulocytes including 
neutrophils and mast cells are the second largest constituent [64]. It is worth noting, however, 
that cell population in the female reproductive tract varies throughout the menstrual cycle which 
could be a result of the fluctuation of hormones [68].  
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1.3.2 Rationale for lymph node targeting in HIV 
There is evidence showing that HIV infected DCs could be detected in the draining lymph nodes 
as early as 18 hours after viral inoculation [69]. By using the rhesus macaque vaginal 
transmission model, Hope et al. also shown that infection in the local draining lymph nodes 
could be detected at 48h when a high dose of SIV based particles was inoculated [70]. In 
addition, as adequate amount of HIV targeted T cells exist in the draining lymph nodes, HIV can 
replicate rapidly in these nodes during the first week of infection [19]. More importantly, 
previous studies have shown that exposing HIV intravaginally increased the expression of 
chemokine macrophage inflammatory protein-3α (MIP-3α) in the endocervical epithelium, 
which attracted plasmacytoid dendritic cells (pDCs) to submucosa, and subsequently induced the 
secretion of MIP-1β. As a consequence, large number of HIV target CD4+ T cells were recruited 
from the draining lymph nodes to the cervicovaginal tissue which exacerbated the local 
expansion and infection [71]. Therefore, a more effective strategy would be one which 
suppresses the early infection in the draining lymph nodes in addition to the portal of viral entry. 
With the protection at the site of lymph nodes, the infiltrated target cells will be guarded by 
antiretroviral drug prior to HIV exposure.  
Even from the standpoint of HIV treatment, antiretroviral drugs need to be delivered to 
lymphatic system as well for improved efficacy. Lymph nodes and other lymphatic tissues act as 
major reservoirs of HIV infection in vivo [73]. The detection of HIV in the blood, is coupled 
with high levels of HIV in the mononuclear cells located in the lymph nodes, mainly T cells, B 
cells, natural killer cells, and macrophages. In addition, the presence of a large number of HIV 
target cells in the lymph nodes increases the viral burden 5- 10 times in the lymph nodes 
compared to the blood. Similarly, viral replication in the nodes has been reported to be 
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approximately 10-100 times higher than that in the peripheral blood mononuclear cells [72]. 
Even if highly active antiretroviral therapy (HAART) can reduce plasma viral loads in HIV-
infected patients by 90%, active virus can still be isolated from lymph nodes after 30 months of 
this therapy [72, 73]. With regard to these findings, delivery of anti-retroviral drugs to the lymph 
nodes will maximize therapeutic effects and might eradicate the established HIV infection.  
 
1.3.3 Current strategies for lymph node drug delivery 
Lymphatic targeting has been utilized for both therapeutic and diagnostic purposes. The major 
applications of lymphatic drug targeting include (1) delivery of anticancer agents to the regional 
lymph nodes in order to prevent tumor metastasis [74-76]; (2) localization of diagnostic agents, 
like Quantum dots and blue dyes, to sentinel lymph nodes before biopsy or dissection  in cancer 
patients [77-79]; and (3) improvement of bioavailability of macromolecular drugs, such as 
peptides and proteins, via selective uptake by the Peyer’s patch in the intestine [80-82].  
Although drug delivery to the lymph nodes has been particularly difficult to achieve, 
increasing attention has been drawn to the development of nanoparticles. This is based on the 
recent understanding that colloidal particles in the interstitium can be recognized by lymphatic 
system and transported into the regional lymph nodes. By definition, colloid particles are 
insoluble substances that can be uniformly dispersed in a medium. Colloidal materials, such as 
liposomes, emulsions, dendrimers, and solid lipids nanoparticles, have been reported to transport 
drug agents to lymphatic tissues [83-87].   
Currently, there are two approaches for lymphatic drug delivery, namely passive 
targeting and active targeting. Passive targeting mainly depends on simple diffusion or some 
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specific formulation properties such as particle size and surface charge. For instance, the size of 
nanoparticles has to be large enough to circumvent direct blood absorption before entering 
lymphatic vessels [73]. In some other scenarios, the fate of drug transport and localization in the 
lymphatic system cannot be modified unless different routes of administration are applied [80]. 
In comparison, active lymphatic targeting is ligand dependent. It relies on the attachment of 
targeting ligands on the surface of nanoparticles for specific receptor binding at the target site 
[88]. It has been suggested that phagocytosis by macrophages is one of the important 
mechanisms associated with nanoparticle uptake in lymph nodes [89, 90]. Therefore, surface 
modification of nanoparticles with ligands that can specifically bind to the receptors expressed 
on macrophages or other antigen presenting cells can significantly improve the efficiency of 
lymphatic targeting [75, 91, 92]. The targeting ligands that are commonly used include 
monoclonal antibodies (mAbs), antibody fragments, and peptides [80, 93].  
Drug delivery to the lymph nodes can be achieved through different routes of 
administration. Generally, to attain therapeutic effects in the regional lymph nodes, the instilled 
colloid particles have to first drain from the site of administration and then preferentially migrate 
to the draining lymph nodes. Due to the existence of the physical barriers such as mucus, 
epithelium, or epidermis, traditional approaches all require needle injections so that drugs can be 
carried to the interstitial space directly. The most frequently used methods include intravenous 
(i.v) injection, subcutaneous (s.c) injection, intramuscular (i.m) injection, and intraperitoneal 
(i.p) injection [92, 94-96]. With i.v administration, the relative drug exposure in lymph versus  
blood could be determined by drug hydrophobicity, plasma protein composition, and lipoprotein 
binding. Instillation of highly hydrophobic drugs after high fat meals usually result in an 
increased drug concentration in the lymph [97]. Subcutaneous administration is another 
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commonly used approach for lymphatic delivery [96, 98, 99]. The major barrier associated with 
this route of administration is the poor drainage though the interstitium to the initial lymphatic 
vessels. Size of colloid nanoparticles has been reported as the principle factor on the rate of 
lymphatic drainage after subcutaneous injection [94]. Smaller colloids could lead to an easier and 
faster uptake.  
Recently, non-invasive routes of administration (with no needle injections) as a new area 
of interest have started to be explored. The application of this new approach includes drug 
targeting to the pulmonary lymph nodes via nasal inhalation [100-103] and genital lymph node 
drug delivery via intravaginal administration. To date, there are three studies that investigated 
lymph node targeting via intravaginal instillation  [104, 105]. One study investigated the 
migration of quantum dots to genital lymph nodes after vaginal instillation in mice. Another 
study explored T cell priming in the genital lymph nodes after intravaginal immunization. 
Notably, the vaginal epithelium in both studies, however, was pretreated with the permeation 
enhancer N-9. This pre-exposure disrupts the epithelium which most likely allowed drug 
exposure in the interstitium. This disruption is not applicable for HIV prevention since it will 
allow direct access for infectious HIV-1 to the target cells in the tissue. Only the third study has 
shown the migration of nanoparticles (20-40nm) to draining lymphatic ducts and regional lymph 
nodes at 1h without any treatment with sexual hormones, epithelial disruptors (N-9), or adjuvants 
[106].  The goal of the present dissertation was to investigate whether this non-invasive approach 
(without using N-9) could be applied to deliver microbicide drug candidates to draining lymph 
nodes after intravaginal administration.  
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1.3.4 Physicochemical properties of lymphatic targeting 
Physicochemical properties can change biodistribution of nanoparticles in vivo and have 
significant effects on the efficiency of lymphatic drug delivery. The major properties that play a 
role include particle size, surface charge, hydrophobicity, molecular weight, concentration, and 
volume [107].  
Particle size is one of the most important factors for lymphatic drug delivery. Particles 
that are smaller than a few nanometers (< 10 nm) can exchange freely through the blood 
capillaries and directly drain in the blood circulation at the site of administration. In contrast, 
particles with diameter around 100 nm can be absorbed in the lymphatic capillaries quickly and 
pass through the lymph nodes rapidly as well. As for larger particles (a few hundred 
nanometers), even though they could be trapped in the interstitium for a longer period of time 
before entering the lymphatic vessels, they retain well in the lymph nodes [88, 108]. In light of 
these findings, if lymph node retention is required for a diagnostic or therapeutic effect in the 
lymph nodes, larger particle sizes will be beneficial since they can stay longer in the nodes [80, 
98]. 
The effect of surface charge on lymphatic uptake has been investigated using liposomes. 
Results indicated that negatively charged liposomes showed faster lymphatic drainage when 
compared to positively charged liposomes after i.p administration [91, 109]. Generally, for 
lymphatic drug delivery, a particular order was followed: negatively charged nanoparticles are 
better than positively charged,  followed by the neutral ones [110]. 
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Hydrophobicity of the nanoparticles is another important factor since it is closely 
associated with phagocytic responses. Hydrophobic materials are more likely to be opsonized 
and transported to the draining lymph nodes than the hydrophilic ones [111]. Surface 
modification with polymers such as polyethylene glycols can modify the hydrophobicity of 
nanoparticles, which will in turn change the rate and extent of lymphatic uptake.  
 
1.4 MICROBICIDE CANDIDATE FOR HIV-1 PREVENTION 
1.4.1 Non-specific microbicide candidate 
Topical PrEP was originally termed as microbicide. The first generation of drugs evaluated as 
vaginal microbicides did not specifically target the HIV life cycle. They were detergents, 
surfactants, acidifying agents and anionic polyanions. One surfactant product nonoxyol-9 (N-9) 
was evaluated in a phase 2/3 clinical trial. Results showed that the use of N-9 did not reduce, but 
instead increased the rate of male-to-female HIV transmission because N-9 induced epithelial 
disruption and genital mucosal inflammation [112-114]. 
Acidifying agents BufferGel and Acidform were developed as bioadhesive vaginal gels. 
These products were designed to maintain the acidic microenvironment in the female 
reproductive tract. Clinical studies have shown that both BufferGel and Acidform were safe for 
vaginal application, however, not effective for the prevention of vaginal HIV transmission [115, 
116].  
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Anionic polyanions such as Carraguard gel, cellulose sulfate gel, cellulose acetate 
phthalate (CAP) gel, and PRO2000 were also evaluated as microbicides. These gels are 
negatively charged which facilitate their interactions with the envelope proteins presenting on the 
surface of the virus. Ideally, this interaction interferes with viral attachment to the CD4
+
 T cells, 
and subsequently compromises HIV infection.  A phase 3 study has shown that Carraguard was 
safe but not effective against the vaginal transmission of HIV [117]. The investigation of 
cellulose sulfate gel effectiveness was terminated early due to the increased HIV infection rate at 
an interim analysis [118]. In addition, CAP gel was evaluated in a phase 1 trial, and this trial was 
stopped due to gel leakage and user complaints [119]. The efficacy of PRO2000 gel was 
examined in two large-scale effectiveness trials [115, 120]. The phase 2b trial found that 0.5% 
PRO2000 gel was safe for use, however, it only reduced the risk of HIV infection by 30%, which 
was not statistically significant [115]. To further understand the effectiveness of PRO2000 gel, a 
gel product containing a higher concentration of PRO2000 (2%) was assessed in a phase 3 trial,  
and results of which showed that no efficacy was found after 2% PRO2000 gel intervention 
[120].  
 
1.4.2 Current microbicide candidates 
As the first generation of non-specific microbicide candidates did not provide desirable efficacy 
in vivo, attention has shifted to compounds that have specific targets in the process of HIV 
replication. In the HIV life cycle (Figure 2), HIV first binds to a CD4 receptor and a co-receptor, 
CCR5 or CXCR4, on the surface of a CD4
+
 T lymphocyte [121]. The virus then fuses with the T 
cells and release its RNA into the host immune cells. After that, single-stranded HIV RNA is 
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converted into double-stranded HIV DNA via reverse transcriptase (RT). Once the reverse 
transcription is complete, HIV DNA penetrates into cell nucleus and inserts itself to the DNA 
sequence of the host cells with the assistance of another viral enzyme, integrase. Afterwards, 
double stranded HIV DNA is unwound and the complementary messenger RNA is synthesized 
to build new long chain viral proteins. The new proteins were then cut into smaller proteins by 
enzyme protease and these smaller proteins are recombined for maturation and released out from 
the host cells.  
Currently, inhibitors that can specifically stop viral fusion, reverse transcription, 
integration, and maturation are being investigated as microbicide candidates. Griffithsin, PSC-
RANTES, and maraviroc are fusion/entry inhibitors which interfere with viral fusion [122-124]. 
The inhibitors blocking the activity of reverse transcriptase include NtRTIs and NNRTIs. TFV is 
an NtRTI which has to be activated prior to being pharmacologically active in vivo by two steps 
of phosphorylation. The CAPRISA 004 trial performed in South Africa has shown that TFV 1% 
vaginal gel was safe to use [121]. This coitally dependent application was found to be effective 
with a 39% reduction in the HIV acquisition. Especially among women with high adherence, 
HIV incidence in the TFV gel arm was 54% lower than the placebo gel arm. This study proved 
the possibility of utilizing vaginal microbicides for HIV prevention. In comparison to the 
NtRTIs, NNRTIs do not need to be converted to active forms in vivo and they are generally very 
potent with activity in the nanomolar concentration. The issue, however, associated with 
NNRTIs is that many are very hydrophobic in nature. Pharmaceutical strategies have to be 
applied to increase their solubility in order to obtain efficacy. DPV is an NNRTI which has been 
intensively investigated. A DPV containing intravaginal ring has been developed for extended 
use and this product is currently under investigation in a phase 3B open-label follow-on trial 
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(MTN-025). Integrase inhibitors are another category of inhibitor which impedes HIV DNA 
incorporation into host DNA. The integrase inhibitor MK-2048 is in development for phase 1 
clinical study. Currently, many protease inhibitor products such as indinavir and saquinavir have 
been approved by FDA for HIV treatment, and some of these are under investigation as 
microbicide candidates [125, 126]. 
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                                                    Figure 2 HIV life cycle.  
1.Binding and fusion: HIV binds to a CD4 receptor and a co-receptor, CCR5 or CXCR4, on the 
surface of a host cell and release its RNA into the host immune cells.  2. Reverse transcription: HIV 
RNA is converted into a double-stranded HIV DNA via reverse transcriptase (RT). 3.  Integration: 
HIV DNA penetrates into cell nucleus and inserts itself to the DNA sequence of the host cells. 4. 
Transcription: Double stranded HIV DNA is unwound and its complementary messenger RNA is 
synthesized to build new viral proteins. 5. Assembly: HIV proteins is then cut into smaller proteins 
by enzyme protease and these smaller proteins are recombined for maturation. 6. Budding: The 
newly assembled HIV will be released from the host cells.  
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1.4.3 CSIC as a microbicide candidate for HIV prevention  
 
 
 
Figure 3 Chemical structure of microbicide drug candidate CSIC 
 
 
 
5-chloro-3-(phenylsulfonyl) indole-2-carboxamide (CSIC) is another highly potent NNRTI with 
an half maximal effective concentration (EC50) value about 1nM  [127]. The chemical structure 
of CSIC is shown in Figure 3. CSIC has been shown to inhibit the activity of HIV reverse 
transcriptase in a tight binding mode [128]. The binding pocket for CSIC is directly below the 
polymerization site of the RT. This type of binding allows for a butterfly conformation and 
strong interactions (Figure 4) [129, 130]. The high affinity binding between CSIC and RT leads 
to a prolonged enzyme inhibition, thus allowing extended antiretroviral bioactivity even after 
drug has been removed (memory effects). A previous study has shown that pretreating 
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uninfected cells with CSIC protected the cells from subsequent HIV challenge [128]. Also, pre-
exposing CSIC to the infected cells eliminated the infectivity of nascent virus and prevented cell-
to-cell HIV transmission. 
 
 
 
 
 
 
Figure 4 Model of HIV reverse transcriptase (Copyright (2008) National Academy of Sciences, U.S.A.) 
Rilpivirine, a close analog of dapivirine, is located in the NNRTI binding site. The polymerization 
site is represented by the fingers and thumb domains. 
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In addition to its high potency and memory effects, CSIC exhibits superior resistance 
properties. Firstly, CSIC was found to possess improved bioactivity to the mutant reverse 
transcriptase K103N and Y181C [131]. More importantly, CSIC presented limited systemic 
exposure after topical exposure, which might reduce the chance of HIV tolerance and circumvent 
retrovirus evolution through drug treatments [128, 132].  
Despite these promising characteristics of CSIC, the major challenge associated with 
vaginal delivery of CSIC is its hydrophobicity. Because of the aqueous environment in the 
vaginal lumen, CSIC must be formulated using effective pharmaceutical drug delivery strategies 
which enhance its aqueous solubility.  
 
1.5 HYPOTHESIS AND SPECIFIC AIMS 
CSIC is a highly potent anti-HIV agent with a promising resistance profile. It prevents HIV 
infection by interfering with the activity of viral reverse transcriptase and blocking the 
conversion of HIV RNA to HIV DNA in the host immune cells.  As the HIV target cells are 
mainly located in the cervicovaginal tissue and the draining lymph, it is essential to deliver CSIC 
or other antiretroviral drugs to both sites of action.  The hydrophobicity of CSIC is favorable for 
tissue penetration and lymphatic drug delivery; however, before it gets into the tissue, the drug 
has to remain stable in the acidic aqueous vaginal lumen, release from formulations, and filter 
through the cervicovaginal mucus. Therefore, a series of preformulation studies are warranted to 
investigate the physicochemical and biological characteristics of CSIC. Pharmaceutical strategies 
that can increase the drug aqueous solubility were utilized to design formulations for vaginal 
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application. The first part of this dissertation was focused on the development and evaluation of a 
water-soluble polymeric film product containing co-solvents for increased encapsulation of 
CSIC. As polymeric films have been successfully used to load hydrophobic NNRTI DPV [36], it 
was worthwhile to develop a polymeric film formulation containing co-solvents in order to 
deliver a high amount of CSIC to cervicovaginal tissue.  
In the second part of this dissertation work, CSIC nanocrystals were prepared to 
investigate its potential application for improved tissue penetration and lymph node drug 
delivery. Nanocrystals are pure drug particles with a particle size controlled by the surrounding 
stabilizers. Since drug particles are not encapsulated in any carrier system, the hydrophobicity of 
the drug can be preserved, which can facilitate tissue penetration. Additionally, rational choice of 
stabilizers can allow nanocrystals to rapidly penetrate the mucus barrier, making lymph node 
drug delivery possible after intravaginal administration.  
 
In this dissertation, we hypothesized that the hydrophobic microbicide candidate 
CSIC can be formulated in a polymeric vaginal film and a nanocrystal formulation with 
high loading capacities using multiple formulation strategies. We further hypothesized that 
the nano-delivery strategy can improve cervicovaginal tissue drug penetration and achieve 
lymphatic drug delivery. 
 
This hypothesis was addressed through the following specific aims.  
 
Specific aim 1: Formulation of a polymeric film containing hydrophobic NNRTI CSIC. 
Preformulation studies were conducted under this aim to investigate the physicochemical 
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properties of the drug. A compatibility study was performed to identify the polymers and 
solvents that can be used in combination with CSIC. This data was used to manufacture a stable 
film formulation with sufficient drug loading.  (Chapter 2 and 3) 
 
Specific aim 2: Formulation and evaluation of CSIC nanocrystals. The physicochemical 
properties of the nanocrystal, such as size, charge, and crystallinity were evaluated. Intracellular 
uptake profile of the nanocrystal and its mechanism of uptake were also investigated. We 
expected to have a formulation with enhanced saturation solubility, increased drug loading 
capacity, and rapid intracellular uptake. (Chapter 4) 
 
Specific aim 3: Investigation of cervicovaginal tissue permeation ex vivo and genital 
lymph node targeting of CSIC nanocrystals. A tissue permeability study was carried out using 
excised human cervicovaginal tissue. In vivo drug distribution in the cervicovaginal tissue and 
the draining lymph nodes were also investigated over time using a mouse model. We expected to 
observe improved tissue penetration and lymph node drug delivery in mice.  (Chapter 5) 
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2.0  PREFORMULATION EVALUATION OF CSIC 
2.1 INTRODUCTION 
As described in chapter 1, CSIC is a potent non-nucleoside reserve transcriptase inhibitor 
(NNRTI). It tightly binds to reverse transcriptase which leads to enhanced antiretroviral activity. 
Given these properties, CSIC is a promising new microbicide candidate. Before formulating 
CSIC into any specific dosage form, detailed preformulation studies are required to obtain 
critical information about the drug substance for the development of safe and effective 
formulations.  
Studies in a preformulation investigation include: (1) assessment of drug solubility in 
various solvents such as water, polyethylene glycols, glycerin, Tweens, ethyl alcohol, methanol, 
etc.; (2) determination of drug partition coefficient; (3) evaluation of crystal properties including 
the crystal habit, crystallinity, and polymorphism; (4) chemical stability in solution and in the 
solid state under conditions typical for formulation, long term storage and administration. Factors 
that could impact a drug’s stability include elevated temperature, high humidity, variable pH, and 
the presence of oxidants or light. When the test drug is a New Chemical Entity, typically a 
stability study will be conducted to evaluate its long term stability under specific temperature/ 
humidity conditions including accelerated conditions. In addition, in some cases, drug stability is 
investigated in the presence of other excipients to evaluate any potential incompatibilities. 
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In the current work, a series of CSIC preformulation evaluations were conducted to 
provide the information required for the development of desirable vaginal microbicide products. 
Firstly, the hydrophobicity of CSIC was determined based on its solubility in multiple solvents 
and partition coefficient. Solid state properties of CSIC were also assessed by its size, shape, 
surface morphology, and melting point. Furthermore, the stability of drug under variable pH, 
temperature, oxidation, and photolysis conditions were investigated as per international 
conference on harmonization (ICH) Q1A (R2) guidelines [133]. Lastly, cytotoxicity of CSIC in 
epithelial cell line HEC 1A and murine macrophage cell line J774A.1 was performed to evaluate 
the compatibility between test substance and HIV target cell types.  
The majority of the studies conducted as part of the preformulation evaluation of CSIC 
explored its intrinsic properties. Studies also included various conditions that can be encountered 
in vaginal environment under physiological and pathophysiological settings. For example, it is 
well known that the normal pH of vaginal fluid is in the 3.5-4.5 range, however, elevated vaginal 
pH can be observed under various conditions, such as on the days prior to and during 
menstruation (6.6) [25], after bacterial infection (5-0-6.5), menopause (6.0-7.5) [28], and in the 
presence of semen (7.0-8.0) [134]. Therefore, a wide range of pH was utilized to assess CSIC 
stability. Consideration of these biological factors will permit a rational design for robust vaginal 
products. 
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2.2 MATERIAL AND METHODS 
2.2.1 Materials  
CSIC was obtained from Dr. Parniak from School of Medicine, University of Pittsburgh. It was 
originally synthesized by Dalton Laboratories (Toronto, ON, Canada) with a purity of >98%. 
The molecular weight of CSIC is 334 g/mol. Thiazolyl blue tetrazolium bromide was obtained 
from Sigma-Aldrich (St. Louis, MO, US). Polyethylene glycol 400 (PEG 400), propylene glycol, 
and glycerin were obtained from Spectrum (Gardena, CA, US). Polyethylene glycol 4000 (PEG 
4000) was obtained from Dow Chemical Company (Midland, MI, US). Bovine serum albumin 
(BSA) was obtained from Spectrum (New Brunswick, NJ, US). Acetonitrile and trifluoroacetic 
acid were purchased from Spectrum and Thermo Scientific respectively (HPLC grade). All other 
chemicals were analytical grade.  The human epithelial cell line, HEC-1A, was purchased from 
American Type Culture Collection (ATCC).  The mouse macrophage cell line, J774A.1, was 
generously provided by Dr. Kerry Empey from the School of Pharmacy, University of 
Pittsburgh. 
 
2.2.2 Methods  
2.2.2.1 High performance liquid chromatography (HPLC) analysis  
CSIC (and possible degradants) were quantified using reverse phase HPLC with a 
Gemini C18 column 4.6x150mm (Phenomenex, Florence, CA), with UV detection at 302 nm. 
The mobile phase comprised a gradient of 0.08% TFA in water (A) and 0.05% TFA in 
 34 
acetonitrile (B), starting with 30% B and a linear increase to 50% B for 15 minutes, followed by 
a hold at this composition for 1 minute, then return to 30% B for equilibration over a period of 4 
minutes. Flow rate was 1.4 ml/min. The limit of detection (LOD) and limit of quantification 
(LOQ) were determined based on Signal-to-noise approach according to ICH Q2(R1) 
guideline[135]. The signal measured from CSIC samples with known low concentrations were 
compared with those of black samples. The signal-to-noise ratios set for the detection limit and 
quantification limit were 3:1 and 10:1, respectively. 
 
2.2.2.2 Solubility  
CSIC solubility was determined in water, vaginal fluid simulant, 40% and 100% 
acetonitrile, PEG 400, propylene glycol, glycerin, 1%, 2.5%, 5% and 10% BSA, and 0.1%, 0.5%, 
and 1% cremophor. 5mg drug was added in 1.5 mL of each solvent. The mixtures were rotated 
using a rotator (Rotator-Gene™, Scientific Industries, speed 2) at room temperature for five 
days. The excess amount of drug was removed by centrifuge at 14,500 rpm (14,100 xg) for 5 
minutes using a eppendorf MiniSpin® plus centrifuge. Samples were filtered through 0.22 µm 
PTFE filters before HPLC analysis. 
 
2.2.2.3 Octanol/water partition coefficient (Log Poct/wat) determination  
The octanol/water partition coefficient is defined as the ratio of drug solubility in non-
polar octanol phase to its solubility in aqueous water at equilibrium. In the current study, octanol 
and water were mixed at three different ratios, 1:1, 2:1, and 1:2 (v/v), in order to assure that the 
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partition coefficient is a constant. The mixtures were rotated vigorously overnight at room 
temperature to reach equilibration. After excess amount of CSIC was added, the samples were 
placed on a transverse rotator at 24 rpm for 6 minutes, and then centrifuged at 6000 rpm for 3 
minutes.  
The octanol/water partition coefficient was calculated using the following equation:  
log Poct/wat = log( [solute]oct / [solute]deionized water).                                                       (Equation 3) 
Where [solute]oct indicates CSIC concentration in octanol phase, and [solute]deionized water 
denotes drug concentration in the water phase. CSIC dissolved in the octanol phase was 
extracted using acetonitrile at a ratio of 1:100 (v/v). Drug concentrations in the aqueous phase 
were analyzed directly by HPLC. The determined partition coefficient reveals the hydrophobicity 
of CSIC. A value larger than 1 indicate that CSIC is a hydrophobic compound because it has 
higher solubility in octanol phase. In contrast, a value smaller than 1 indicate that the test drug is 
hydrophilic presenting a higher solubility in water.  
 
2.2.2.4 Size, shape and surface morphology of drug substance 
Polarized light microscope 
CSIC was first dissolved in acetonitrile and placed on a glass slide to allow it to air dry. 
Afterward, sample was fixed with Cytoseal
TM
 60. The particle size, shape and surface 
morphology of CSIC were observed using a Zeiss Axioskop 40 inverted phase contrast 
microscope equipped with a polarized light filter, an AxioCam MRc5 color video camera, and 
analyzed by AxioVision Rel 4.7 software.  
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Scanning electron microscope (SEM) 
The physical properties of CSIC were also studied using SEM (Philips XL30 FEG) with a 
10kV accelerating voltage. Before scanning, CSIC powder was mounted on an aluminum holder 
by carbon conductive glue and coated with platinum using a platinum sputter coater.  
 
2.2.2.5 Thermal behavior by differential scanning calorimetry (DSC) 
DSC (DSC 1 with STAR
e
 DB V11.00 software, Mettler Toledo) was performed to 
investigate the melting behavior of the drug substance. Pure drug was placed in aluminum 
crucibles and sealed by a crucible sealing press. The thermograph was obtained by heating 
samples from 25 to 350°C at a rate of 10°C/min with a constant nitrogen purge at 50 mL/min.  
 
2.2.2.6 Stability studies  
For stability studies, buffer solutions were mixed with acetonitrile, which allowed for 
complete drug solubilization. Any drug loss detected over time would thus be a result of drug 
degradation. Drug concentration utilized for this series of studies was determined based on CSIC 
solubility in 40% acetonitrile.   
pH stability  
Standard buffer solutions with pH values of 1.2, 4, 5, 7, 9, and 10 were prepared 
according to United States Pharmacopeia (USP) 26. CSIC was first dissolved in acetonitrile, and 
then mixed with the buffer solution individually to achieve a final concentration of 100μg/mL. 
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Sample solutions were sonicated in a water bath until the drug was completely dissolved. 
Samples were then covered with aluminum foil and stored at room temperature for later analysis. 
Aliquots were taken daily for 10 days, and the drug content was analyzed by HPLC. Individual 
studies were performed in triplicate. 
Thermal stability  
CSIC was dissolved in 40% aqueous acetonitrile at a concentration of 100μg/mL. 
Samples were incubated at 25°C and 65°C. At various times aliquots were taken for analysis of 
drug content by HPLC as described above.  
Oxidation 
CSIC was dissolved in 40% aqueous acetonitrile containing 3% H2O2 (100μg/mL CSIC) 
and then stored at room temperature. At various times aliquots were taken for analysis of drug 
content by HPLC as described above. 
Photolysis  
CSIC solutions (100 µg/mL) were prepared in 40% aqueous acetonitrile and in 40% 
acetonitrile in phosphate buffer (pH 7.0). One half of each sample set was covered in aluminum 
foil, and the samples were all incubated at 30°C/ 65% relative humidity under a fluorescent light 
source (2x 20 watts). At various times aliquots were taken for analysis of drug content by HPLC 
as described above.  
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2.2.2.7  Cytotoxicity  
Cytotoxicity was assessed using HEC-1A human endometrial epithelial cells and 
J774A.1 mouse macrophage cells. Cells were seeded into 96 well plates at a density of 2.5x10
4
 
cells per well for HEC-1A, and 8x10
4
 cells per well for J774A.1. Cells were then treated with 
serially diluted CSIC with drug concentrations ranging from 10µg/mL to 1ng/mL. It was worth 
noting that 0.1% DMSO was added in the samples to facilitate drug solubilization and 
suspension in the aqueous medium. After 24h drug exposure, methylthiazolyldiphenyl- 
tetrazolium bromide (MTT) assay was performed to determine cell viability. Briefly, 
medium in each well was replaced by 180µL cell culture medium and 20 µL MTT solution (5 
mg/mL). MTT was reduced to formazan in purple. After incubation at 37°C for another 3h, 
media was removed, and 200µL of solubilization solution DMSO was added in each well. 
DMSO dissolved the insoluble formazan product into a colored solution. The color of the 
solution was determined by the amount of MTT being reduced. The plates were then covered 
with aluminum foil and agitated on an orbital shaker for 20 minutes. The absorbance was 
measured at 595 nm using a microplate reader (Beckman Coulter DTX 880, USA). 
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2.2.2.8 Statistical analysis 
All results were presented as the mean ± standard deviation (SD). Pairwise differences 
were determined by Student’s t test. In the stability studies, drug concentration determined over 
time is reported as CSIC recovery (% of time zero) ± SD. The differences among groups were 
tested by a repeated measures mixed model with pairwise comparisons using STATA version 13. 
A p value <0.05 was considered statistically significant. By using the mixed models, post hoc 
tests could be conducted and the time could be treated as a continuous variable.  
 
2.3 RESULTS 
2.3.1 HPLC method  
As part of the preformulation studies, an HPLC analytical method was developed and validated. 
Under the conditions used (as described in Methods (2.2.2.1), the retention time of CSIC was at 
10.9 minutes. The LOD was determined to be 0.01 μg/mL, and the LOQ was 0.033 μg/mL. A 
linear standard curve was obtained over a range of 0.5-200 μg/mL(Figure 5). No CSIC 
degradation products were noted via HPLC chromatogram during the analysis. The overlay 
among the ten CSIC chromatograms illustrated the repeatability of samples at the lowest 
standard level (0.5 μg/mL) (RSD< 1%). This developed HPLC method was applied to quantify 
the solubility of CSIC throughout the dissertation work. 
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Figure 5 Linearity rage of CSIC (0.5-200 μg/mL) determined by HPLC. Drug was detected 
by a diode array detector, and the wavelength was set at 302 nm. Data were represented by mean ± 
standard deviation (n=4). The standard deviations all were within the symbols. 
 
 
 
2.3.2 Solubility  
The validated HPLC method was used to determine the solubility of CSIC in various solvents 
presented in Table 1a. Solubility criteria provided in Table 1b were defined according to the USP 
and the British Pharmacopeia (BP) [136, 137]. Specifically, solubility was classified in seven 
different categories in terms of the parts of solvents required to dissolve one part of solute 
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regardless of the solvent chosen.  CSIC is practically insoluble in water, vaginal fluid simulant, 
propylene glycol, glycerin, all the BSA solutions, 0.1% cremophor and 0.5% cremophor; very 
slightly soluble in PEG 400, 40% acetonitrile and 1% cremophor; and slightly soluble in 100% 
acetonitrile.  
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Table 1 CSIC solubility.  
(a) CSIC solubility in commonly used solvents. (b) USP and BP solubility criteria 
 
 
     (a) 
Solvents Solubility Ratio with 
antiviral activity 
(EC50=1nM) 
μg/mL    µM 
MilliQ water 1.44 4.31 4311.38 
Vaginal fluid 
simulant  
30.5 91.32 91317.37 
40% acetonitrile     360 1077.84 1077844.31 
100% acetonitrile 1700 5089.82 5089820.36 
PEG 400 129 386.23 386227.54 
Propylene glycol 53 158.68 158682.63 
glycerin 10.2 30.54 30538.92 
1% BSA 14.21  42.54 42544.91 
2.5% BSA  21.60  64.67 64670.66 
5% BSA  36.05  107.93 107934.13 
10% BSA  55.87  167.28 167275.45 
0.1% Cremophor  18.89 56.56 56556.89 
0.5% Cremophor  48.83 146.20 146197.60 
1% Cremophor  136.65 409.13 409131.74 
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Table 1 (continued) 
 
      (b) 
 
Descriptive terms Parts of 
solvent needed for 1 
part solute 
Solubility 
Very soluble < 1 >1g/mL 
Freely soluble 1-10 0.1-1g/mL 
Soluble 10-30 0.03-0.1g/mL  
Sparingly soluble 30-100 0.01-0.03g/mL 
Slightly soluble 100-1000 1-10mg/mL 
Very slightly soluble 1000-10,000 0.1-1mg/mL 
Practically insoluble  > 10,000 < 0.1mg/mL 
 
 
 
2.3.3 Octanol/water partition coefficient (Log Poct/wat) determination  
The hydrophobicity of CSIC was also determined by the partition coefficient (Log P) which was 
calculated by the logarithm of drug solubility in hydrophobic solvent octanol and hydrophilic 
solvent water (Equation 3). The Log P values of CSIC in the 1:1, 2:1 and 1:2 (v/v) octanol:water 
mixtures were found to be 3.72, 3.69, and 3.72 respectively. The consistent values among the 
various ratios of octanol/water demonstrate that the partition coefficient is a constant. The 
observed partition coefficient greater than 1 demonstrates that CSIC is hydrophobic. Compared 
with the Log P value of DPV (mean predicted log P = 4.73 ± 0.64)[46], CSIC is less 
hydrophobic. 
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2.3.4 Size, shape and morphology 
The physicochemical properties of CSIC such as surface morphology, particle size and shape 
were investigated by polarized light microscope and SEM. Hexagonal prism-shaped crystals 
were observed under light microscope (Figure 6a). The size of the CSIC crystal was not uniform, 
varying from less than 1 μm to over 100 μm. SEM imaging showed that CSIC exists in a 
prismatic form and aggregated in a needle/long rod shape (Figure 6b).  
 
 
 
(a)                                                                                   (b) 
         
 
 
Figure 6 Physicochemical characterization of CSIC.  
(a) Polarized light microscopic image of CSIC (scale bar=20μm) (b) Field emission scanning 
electron microscopy image of CSIC (scale bar=5μm)  
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2.3.5 Thermal behaviors of CSIC 
DSC thermograms showed a downward endothermic peak at 257°C which indicates the 
transition of CSIC powder from a crystal form to a liquid form. The peak temperature reveals its 
melting point (Figure 7). The presence of one sharp peak suggests that CSIC exists as a single 
crystal arrangement with no polymorphism. 
 
 
 
 
 
 
Figure 7 DSC thermograph of CSIC.  
Melting point of CSIC was observed at 257°C. 
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2.3.6  Stability studies  
The susceptibility of drug across a wide range of pH was investigated for potential hydrolytic 
degradation (Figure 8a). CSIC was found to be stable under all pH conditions for at least 10 days 
(<5% of drug loss). At each time point, more than 95% of the drug was detected compared to the 
drug concentration at time zero.  
In the thermal stability study, the concentration versus time profiles for CSIC exposed to 
25°C/60% RH and 65°C were plotted. Results showed that CSIC was stable under both thermal 
conditions and drug concentrations remained unchanged for more than 10 days (Figure 8b). 
Upon H2O2 exposure in the oxidation study, a trend of drug loss was observed over time, 
however, no statistical difference could be found at the end of 10 days in comparison to Time 0 
(Figure 8c).  
For the photolysis stability study, CSIC stored in the dark was found to be stable for at 
least 12 days. In comparison, drug concentration declined over time in samples that were 
exposed to light. After 144 hours, a significant difference in drug content was confirmed between 
samples stored in light and samples stored in dark (Figure 8d). The indole moiety of CSIC may 
contribute to the photosensitivity of this drug. The susceptibility of CSIC to light, however, is not 
a significant problem in the final solid film formulation of CSIC.   
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(c) 
 
(d) 
 
 
 
Figure 8 CSIC stability profiles.  
CSIC stability (a) at various pHs, (b) in 25°C/60%RH and 65°C environmental chambers, (c) in 3% 
H2O2  solution at 25°C, and (d) with or without fluorescent illumination (2 x 20 watts) exposure in 
water or pH7 phosphate buffer solution respectively . Each point represents mean ± SD (n=3) 
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2.3.7 Cytotoxicity  
Some degree of dose-dependent cytotoxicity was noted in both HEC-1A and J774A.1 cell lines 
exposed to CSIC, with the 50% cytotoxic concentration (CC50) of CSIC for both cell lines 
greater than 5µg/mL (Figure 9). This CC50 value is several orders of magnitude higher than the 
antiviral EC50 of CSIC (15µM vs. 1nM), providing an in vitro selectivity index of 15,000. This 
suggests that CSIC is a reasonably safe candidate for pre-exposure prophylaxis use.  
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Figure 9 In vitro cytotoxicity of CSIC against cell line HEC-1A and J774.A1. 
The cytotoxicity of CSIC was measured at concentrations ranging from 10µg/mL to 1ng/mL. 0.1% 
DMSO was added in the samples to facilitate drug solubilization and suspension in the aqueous medium. 
Following 24h drug treatment,  cell viability was determined by MTT assay. The absorbance was 
measured at 595 nm using a microplate reader (Beckman Coulter DTX 880, USA).Each point represents 
mean ± SD (n=6) 
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2.4 DISCUSSION AND CONCLUSION 
The overall goal of the preformulation studies conducted in this chapter was to evaluate the 
physicochemical and biological properties of the active pharmaceutical ingredient (API) and its 
stability profile under various conditions to identify factors that could potentially lead to 
formulation problems. The test article CSIC is found to be highly hydrophobic according to its 
poor solubility in various solvents and the determined partition coefficient (LogP >1). As a 
consequence, the hydrophobic nature of CSIC will significantly impact its dissolution rate in the 
aqueous vaginal fluid [24]. In addition, the drug’s bioavailability in vivo will be compromised as 
well since the drug molecules have to be dissolved first to be absorbed [138]. Therefore, 
formulating CSIC in vaginal products would be very challenging and the majority of work will 
be focused on solubility improvement.  
In addition to the drug solubility study, crystal properties of CSIC were evaluated. As 
observed under polarized light microscope and SEM, CSIC possessed a needle shape crystal 
structure which indicated that the growth of CSIC crystals was faster in one dimension. In 
addition, the experiment carried out by DSC identified the melting point of the raw drug. As 
pharmaceutical companies prefer to market drugs that are stable at ambient temperature (25°C), 
the melting point of CSIC at 273°C approved its suitability as a promising drug candidate. This 
information will be compared with the nanocrystal formulation described in the Chapter 4 to 
confirm the successful preparation of the nano-sized CSIC crystals.  
Chemical stability of API is of great importance since it affects the safety and efficacy of 
the drug substance. The stability studies were designed according to the ICH guidelines [133]. 
The goal of the stability evaluation is to monitor the quality and quantity of CSIC under stress 
conditions over time. The resulting data can help identify the potential degradation 
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product/pathway, validate the power of the developed analytical procedures, select appropriate 
formulation and dosage form, and determine appropriate package requirement and storage 
conditions.  
As part of the stability study, the susceptibility of drug across a wide range of pH was 
investigated for potential hydrolytic degradation. Hydrolysis is a chemical reaction, which 
decompose drug substance under acidic and basic conditions via reaction with water. CSIC was 
found to be stable under all pH conditions for at least 10 days (<5% of drug loss). No 
degradation peaks could be detected by HPLC. The desirable stability profile of CSIC will make 
it suitable for vaginal drug delivery.  
In the thermal stability study, two storage conditions were chosen: 25°C/60% RH and 
65°C. The 65°C was introduced as stress, which may increase the rate of degradation if it exists. 
Data showed that the API was very stable under both temperatures for at least 10 days which was 
a positive finding indicating the drug might have a long shelf life.  
During the process of formulation, storage, handling and application in vivo, there are 
many resources that could oxidize the drug, such as the use of organic solvents and excipients in 
formulations, and, biologically, the hydrogen peroxide produced by Lactobacillus in the female 
reproductive tract. In the current study, 3% hydrogen peroxide was utilized to test CSIC’s 
oxidative stability. This concentration was chosen since it has been commonly used in the 
pharmaceutical field to identify the relevant degradation products [139, 140]. It was found that 
no significant drug loss or apparent degradants were observed by the end of 10 days. To note, the 
lactobacillus in vivo only secretes 0.02% of hydrogen peroxide, which is much lower than the 
3% used in the current study. Therefore, the result suggests that CSIC could be stable under 
oxidative environment.  
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Photolysis was also investigated for CSIC in the current preformulation study. As shown 
in the result section, CSIC is photosensitive and has potential for photodegradation. Further 
studies may need to be conducted to investigate the corresponding degradation products. This 
finding has an influence on sample handling, manufacturing, packaging and product labeling, 
which is elaborated in the following studies.    
To assess the safety profile of the API in cells, the cytotoxicity profiles of this drug were 
evaluated in epithelial cell line HEC 1A and mouse macrophage cell line J774A.1. It is well 
known that epithelial cells in the female reproductive tract are the primary site of sexually 
transmitted HIV infection and act as a physical barrier against the initial HIV acquisition [16, 
141]. Any damage to the epithelium will result in an increased risk of infection. It is critical to 
maintain the integrity/ viability of epithelia when developing vaginal delivery products, 
especially for HIV prevention [112, 142]. In addition, HIV also targets macrophages in the 
female reproductive tract. These cells are actively involved in the phagocytosis of exogenous 
components and the transport the virus to the draining lymph nodes which facilitates the 
establishment of systemic infection [16]. Therefore, the cytotoxic information of the drug to both 
the epithelium and macrophages are essential for future biological evaluations. Based on the 
results generated from the cytotoxicity study, a dose-dependent reduction in cell viability was 
observed. A non-toxic concentration, 5 μg/mL, was chosen for the cell based study described in 
Chapter 4. This concentration should be able to provide sufficient anti-HIV activity since it is 
several orders of magnitude higher than the EC50 of CSIC (~0.3 ng/mL) [128, 143]. 
In conclusion, the preformulation evaluation preformed in this chapter proved CSIC as a 
promising drug candidate for vaginal drug delivery since it is stable under many stressed 
conditions.  The studies in this chapter also identified the major challenge for CSIC formulation 
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development and bioavailability, which is its hydrophobicity. The use of pharmaceutical 
strategies is highly recommended to improve CSIC aqueous solubility. To date, numerous 
pharmaceutical strategies have been developed and applied to improve aqueous solubility of 
hydrophobic drug candidates, such as crystal modification, amorphization, particle size 
reduction, solid dispersion, co-solvents, cyclodextrin complexations, self-emulsification [50, 51, 
144]. In this dissertation work, co-solvent and solid dispersion strategies were applied in 
combination to improve the aqueous solubility of CSIC in a vaginal film formulation (Chapter 
3). Moreover, a nanocrystal formulation was developed utilizing the particle size reduction 
approach to enhance CSIC solubility (Chapter 4). 
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3.0  FORMULATING CSIC IN WATER SOLUBLE POLYMERIC FILM USING 
COSOLVENT AND SOLID DISPERSION STRATEGIES 
3.1 INTRODUCTION 
As discussed in Chapter 2, CSIC is a highly potent non-nucleoside reverse transcriptase inhibitor 
(NNRTI). The major challenge for the vaginal delivery of CSIC, however, is its hydrophobicity. 
Research on strategies to improve drug’s aqueous solubility is, therefore, warranted. In this 
chapter, cosolvent and solid dispersion strategies were utilized as means to increase CSIC 
solubility. These approaches helped loading a high dose of drug in a water soluble polymeric thin 
film.  
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Cosolvents are defined as water miscible organic solvents that can be used in liquid drug 
formulations to increase the solubility and chemical stability of hydrophobic agents [145]. They 
work by reducing the interfacial tension between the aqueous solution and hydrophobic API and 
disrupting the self-association network among water molecules [146]. The technique of using 
cosolvents, cosolvency, has been commonly employed throughout the history of drug 
formulation. Cosolvent system is  favorable due to its safety profile, high loading efficiency, and 
ease of manufacturing [144]. Cremophor EL, one of the most investigated cosolvents, has been 
used to improve the solubility of anticancer drug paclitaxel (Taxol) [147]. Recently, a cosolvent 
system comprising N-methyl pyrrolidinone, ethanol, and Tween 80 was developed to enhance 
the solubility and bioavailability of a hydrophobic drug curcumin [51].  
Solid dispersions refer to the dispersions of active pharmaceutical ingredients (API) in 
inert matrix at solid state. Usually, they are composed of hydrophobic drugs and hydrophilic 
matrixes[148, 149]. When the hydrophilic matrix dissolves in the aqueous medium, the dispersed 
API will be released as very fine, colloidal particles with reduced particle size (<1μm), which in 
turn increase the  solubility, dissolution rate and bioavailability of drug [150]. Recently, solid 
dispersion strategy has been applied in the development of a bioadhesive vaginal film for the 
delivery of a hydrophobic drug itraconazole against vaginitis [151]. During the process of 
manufacturing, itraconazole was dispersed uniformly in film-forming polymers in water, and the 
film product was then prepared by solvent evaporation method. Additionally, in the field of 
PrEP, a solid dispersion of a hydrophobic NNRTI, dapivirine (DPV), was utilized in a vaginal 
film formulation [152]. The results have shown that DPV containing vaginal film provided rapid 
drug release and effective protection against HIV-1 infection both in vitro and ex vivo.  
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Polymeric thin films are an emerging dosage form for vaginal delivery. In addition to 
itraconazole and DPV, vaginal films have been utilized to deliver drug substances such as the 
contraceptive antimicrobial agent sodium  polystyrene sulfonate [153],  the first generation of 
microbicide cellulose acetate phthalate [154], and second generation microbicide tenofovir [155]. 
The development of vaginal films has provided women with more dosage form options and leads 
to an improved user adherence [156, 157].  In comparison to other vaginal products, vaginal film 
presents negligible vaginal leakage, easy application using fingers, discreet use, and low cost 
[37, 152, 158]. Therefore, vaginal film dosage form was chosen for the delivery of CSIC in the 
current work.  
In this chapter, the cosolvent and solid dispersion approaches were both utilized within 
the film formulation for the delivery of CSIC to the vagina. A compatibility study was first 
conducted to identify the polymers, surfactants and cosolvents that could be used with CSIC. A 
ternary phase diagram was developed to optimize the cosolvent system, which facilitated the 
drug dispersion in the film formulation. Once the film products were developed and 
manufactured, a series of evaluations were carried out including drug content, water content, 
tensile strength, disintegration, dissolution, anti-HIV bioactivity, and biocompatibility. These 
properties were monitored over 12 months under different storage conditions to assess drug 
product stability.  
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3.2 MATERIAL AND METHODS 
3.2.1 Materials  
Polyvinyl alcohol (PVA) was obtained from Spectrum (Gardena, CA, US). HPMC 4000 (HPMC 
K4M) was purchased from Colorcon (West Point, US). Polyethylene glycol 4000 (PEG 4000) 
was obtained from Dow Chemical Company (Midland, MI, US). For information about drug 
CSIC and other excipients, please refer to Chapter 2. 
 
3.2.2 Methods 
3.2.2.1 CSIC-excipient compatibility study  
The goal of the compatibility study was to preclude excipients that might induce stability 
issue over time. Test excipients included polyvinyl alcohol, HPMC K4M, PEG4000, PEG400, 
propylene glycol, and glycerin. These were mixed with CSIC individually at a ratio of 1:1 (w/w) 
to assess any potential interactions [159]. Physical compatibility of CSIC with the excipients was 
determined by DSC and compared to that of CSIC alone [159, 160]. Samples were heated from 
25 to 280˚C at a heating rate of 10°C/min with a constant nitrogen purge at 50.0 mL/min. 
  
3.2.2.2 Co-solvent system to increase CSIC solubility  
PEG 400, propylene glycol, and glycerin were selected as cosolvents for CSIC. 
Identification of the optimal ratio of these solvents was carried out by mixing them at different 
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percentages according to the ternary phase diagram shown in Figure 10. Excess CSIC was added 
in each solvent matrix. Samples were then placed on a rotating mixer for 5 days at room 
temperature to allow solubilization. To determine CSIC solubility, samples were centrifuged to 
remove the undissolved drug particles, and the supernatant was used for drug extraction and 
quantification by HPLC as described above. 
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Figure 10 Ternary phase diagram. 
The distance AB’, B’C’’ and C’’A indicate the parts of PEG 400, propylene glycol, and glycerin 
respectively. Outward arrows from each solvent matrix are drawn parallel to the sides of the 
triangle. Any point within the triangle represents a given composition. For example, in the case of 
solvent matrix (S8),  the matrix was composed of 75 parts of A, 50’ parts of B’ and 75’’ parts of C’’. 
The ratio among A, B’ and C’’ was 75:50:75, or 3:2:3.  
 
 
A: PEG 400 
B’: propylene glycol 
C’’: glycerin 
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3.2.2.3 Preparation of CSIC vaginal film  
CSIC film was manufactured using a solvent casting technique as reported previously 
with minor modifications [36]. Briefly, film forming polymer PVA was first dissolved in MilliQ 
water upon heating at 90°C in a water bath. Polymer HPMC K4M and PEG 4000 were then 
added into the PVA solution at room temperature. The polymer solution was stirred overnight 
using an overhead stirrer (Erostar Power Control –Visc, IKA Works, Inc) with a stirring rate at 
50 rpm. CSIC was dissolved in the optimized cosolvent system according to the ternary phase 
diagram, and then added to the pre-prepared polymer solution with stirring over 15 minutes to 
ensure uniform distribution of CSIC. The mixture was then cast onto a preheated film applicator 
(70˚C) to evaporate the excess amount of water (within 15 minutes). Film sheets were removed 
and cut into 1”x2” pieces and then stored in foil packages. 
 
3.2.2.4 Physicochemical characterization of CSIC film  
Standard measurements of the film formulations included weight, thickness, film 
appearance, water content, tensile strength, disintegration time, drug content, content uniformity 
and dissolution. Film appearance was evaluated subjectively by texture and color. Film surface 
morphology was observed by SEM. Water content was determined using the Karl Fisher 
approach (Model 890 Metrohm Titrando and 832 KF Thermoprep). Film tensile strength was 
measured using a texture analyzer (TA-XT.Plus) in combination with a TA 96B probe, and 
calculated using the equation: Tensile strength= Force (kg) / cross-sectional area of film (m
2
) 
(Equation 4). Film disintegration analysis was performed by submerging films into 3 mL MilliQ 
water followed by rotation on an orbital shaker with constant observation. The disintegration 
time was determined when separation of the first piece was observed. To determine the drug 
 62 
content, film matrix was first dissolved in MilliQ water, and CSIC was extracted by mixing with 
70% acetonitrile solution before HPLC analysis. Film drug content uniformity was evaluated by 
cutting a film into six small pieces, and then quantifying the CSIC content in each sample. The 
dissolution profile of CSIC films was tested using a USP class IV method coupled with a 
SOTAX CE7 smart apparatus. 80 mL of 1% cremophor solution with a flow rate of 16mL/min 
used to maintain sink conditions. At predetermined time points, 1 mL samples were collected for 
analysis of CSIC content by HPLC as described in Chapter 2.    
 
3.2.2.5 Film compatibility with Lactobacilli 
Compatibility of CSIC film with seven different Lactobacillus strain were conducted by 
standard microbicide safety techniques [113]. Briefly, Lactobacillus-containing suspension and 
film dissolving solution were incubated together at a ratio of 1:1 (w/w) for 30 minutes at 37°C. 
Colony forming units determined after film exposure were counted and compared with the units 
before film treatment.  
 
 
 
 
 
 
 63 
3.2.2.6 In vitro anti-HIV bioactivity test  
Two types of bioactivity assays were conducted in this study [156], both using single 
replication cycle analysis with P4R5 cells. Direct antiviral activity was assessed by 
simultaneously exposing cells with HIV and various concentrations of CSIC film solutions for 
48h. The protective effect (memory effect) of film-formulated CSIC was assessed by pre-
exposing cells to various concentrations of CSIC film solutions for 2 hours, followed by removal 
of the drug prior to exposure to HIV. In both studies, a single replication cycle assay was used to 
evaluate HIV replication. As a control, similar studies were completed for CSIC substance only. 
CSIC was dispersed in the cell culture medium with the presence of DMSO. 
 
3.2.2.7 CSIC film stability  
Stability studies were carried out according to the Guidance for Industry (Q1A (R2) 
stability testing of new drug substances and products)[161]. Films were individually sealed in 
foil packages and stored in 30˚C/ 65% Relative Humidity (RH) for 12 month as a long term 
study and 40˚C/ 75% RH for 6 months as an accelerated study. At time zero, 15 day, 1 month, 3 
month, 6 month, 9 month, and 12 month, film samples were taken for evaluation.  
 
3.2.2.8 Statistical analysis 
All results were provided as the mean ± standard deviation (SD). Pairwise differences 
were determined by Student’s t test. A p value <0.05 was considered statistically significant.  
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3.3 RESULTS 
3.3.1 CSIC-excipient compatibility study 
Prior to CSIC film formulation development and optimization, the compatibility of CSIC with 
each individual excipient was investigated by monitoring the impact of the excipient on the 
melting point of CSIC. No shifts for the melting point of CSIC were observed when the drug was 
mixed with PVA, HPMC K4M, and propylene glycol separately (Figure 11a-c). When CSIC was 
exposed to PEG 400, its melting peak disappeared indicating the solubilization of CSIC in this 
excipient (Figure 11d). Similar finding was also observed for CSIC/ PEG 4000 mixture. The 
majority of CSIC dissolved in PEG 4000, while the small endothermic peak detected at 253°C 
may arise from a small fraction of undissolved drug (Figure 11e). In contrast, the melting peak of 
CSIC has shifted to a lower temperature at 217°C (Figure 11f) in the presence of glycerin. 
Hydrogen bonding between CSIC and glycerin may result in the decrease of melting 
temperature. Overall, among all the excipients, glycerin was the only one that might cause 
incompatibility issues. It would be very important to reduce the percentage of glycerin use.  
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(a)                                                                                   (b) 
                            
 
 
(c)                                                                                 (d)                              
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(e)                                                                             (f) 
          
 
 
Figure 11 The compatibility between CSIC and each individual excipient evaluated by differential 
scanning calorimetry. 
The melting peak of CSIC did not change when drug was mixed with PVA (a), HPMC K4M (b), 
and propylene glycol (c) separately. Drug dissolved in PEG 400 (d) and PEG 4000 (e). While the 
small endothermic peak detected at 253°C in the CSIC-PEG4000 may arise from a small fraction of 
undissolved drug. In contrast, the melting peak of CSIC has shifted to a lower temperature at 
217°C (f) in the presence of glycerin which might indicate some incompatibility issues.  
 
 
 
3.3.2 Co-solvent system to increase CSIC solubility  
To improve the solubility of CSIC in the film formulation, a co-solvent system including PEG 
400, propylene glycol and glycerin was designed. The three cosolvents were chosen due to their 
favorable safety properties for vaginal application and the ability to improve drug solubility. A 
ternary phase diagram was utilized to optimize the ratio among these three solvents (Figure 10). 
Data showed that the utilization of PEG 400 significantly enhanced the solubility of CSIC 
followed by propylene glycol (Table 2a). Among all the solvent matrixes illustrated in Figure 10, 
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solvent matrix No.15 (S15), which is composed of 50% PEG 400 and 50% propylene glycol, 
presented the maximum solubility of CSIC at 28.64 mg/mL. To further optimize the co-solvent 
system, solvent matrixes containing higher percentages of PEG 400 such as 67.5% and 75% 
were prepared (Table 2b) to achieve even high drug solubilization. Maximum CSIC solubility 
was obtained at 30.2 mg/mL for the solvent matrix No.18 (S18, Figure 10) when the ratio among 
PEG 400, propylene glycol, and glycerin was set at 10: 4: 2 (5:2:1).  
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Table 2 CSIC solubility in different solvent matrixes. 
CSIC solubility in (a) solvent matrixes prepared according to the ternary phase diagram and (b) 
CSIC solubility in solvent matrixes with even higher proportion of PEG 400. The percentage of 
PEG 400 used in each sample is noted in the parenthesis. Solvent matrix 18 represented the highest 
drug solubility. 
 
 
(a)   
Sample 
No. 
PEG 
400 % 
PG % G% Solubility 
mg/mL 
S1 0 50 50 5.23 
S2 12.5 37.5 50 10.60 
S3 12.5 50 37.5 12.85 
S4 25 25 50 12.85 
S5 25 37.5 37.5 17.08 
S6 25 50 25 19.99 
S7 37.5 12.5 50 20.46 
S8 37.5 25 37.5 21.81 
S9 37.5 37.5 25 24.63 
S10 37.5 50 12.5 22.59 
S11 50 0 50 22.86 
S12 50 12.5 37.5 23.67 
S13 50 25 25 24.31 
S14 50 37.5 12.5 28.21 
S15 50 50 0 28.64 
 
(b)   
                                 
 
 
 
 
 
     Sample No. 
Component 
S16 S17 S18    S19     S20 
PEG 400, % 10  
(62.5%) 
10 
(62.5%) 
10 
(62.5%) 
6 
(75%) 
3     
(75%) 
PG, % 2 3 4 1 1 
G,% 4 3 2 1 0 
Solubility, mg/mL 22.7 20.7 30.2 29.1 28.8 
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3.3.3 CSIC film formulation development and characterization  
Polymeric vaginal films comprising PVA, HPMC K4M, PEG 4000, PEG 400, propylene glycol, 
glycerin, and drug CSIC at a ratio of 50:20:20:25:10:5:1 were manufactured using a solvent cast 
technique. CSIC films were soft, flexible, smooth and translucent (Figure 12). No precipitation 
of either drug particles or dehydrated polymers was observed on the film surface. The result 
indicates sufficient water content remaining in the film product to allow for polymer hydration. 
In addition, the percentage of the co-solvents and polymers applied in the current formulation 
were adequate for drug solubilization and dispersion.  
 
 
 
 
 
 
Figure 12 Picture of a CSIC vaginal film (1″ x 2″) 
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Numerous physicochemical properties of the CSIC films were characterized in the 
current investigations. The average weight and thickness of the films were recorded to be 137 ± 
11.5 mg and 133 ± 0.013 µm, respectively. This thickness was adjusted to load sufficient amount 
of drug in each 1″ x 2″ film product. Drug content in CSIC films was quantified to be 1.19 
±0.1 mg, and drug substance was distributed uniformly across the film sheet as well as within 
each individual film (relative standard deviation <5%). The dosing level for CSIC was designed 
based on the dosing regimens used for DPV vaginal film, which is 1.25 mg DPV per film [36]. 
In addition, the residual water in the films was determined to be less than 10% (6.8 ± 0.49%). 
The limited amount of water (<10%) remained in the films will help maintain long term stability 
of the drug substance and film properties. To understand the mechanical property of CSIC films, 
tensile strength was measured. The tensile strength was found to be in the range of 1000-1400 
kg/m
2
 which was
 
relatively lower than that of the vaginal contraceptive films VCF
®
 (1400-2200 
kg/m
2
). Moreover, in the disintegration study, once the films were exposed to water, the 
separation of the first piece was observed within 3 minutes indicating the fast disintegrating 
nature of the films. Also, drug release from the film formulation was evaluated in a class IV USP 
dissolution apparatus. Within three minutes, drug concentrations were detected at 3 μg/mL, 
which is 3 orders of magnitude higher than the EC50 of CSIC (Figure 13).An estimated 50% of 
loaded drug released from the formulation within 10 minutes, and over 85% of drug released in 
60 minutes. The results generated from the dissolution study confirmed the fast dissolving 
property of the vaginal film which was similar to the DPV containing vaginal film [36].  
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Figure 13 Dissolution profile of CSIC film at time zero  
The dissolution profile of CSIC films was tested using a USP class IV method coupled with a SOTAX CE7 
smart apparatus. 80 mL of 1% cremophor solution with a flow rate of 16mL/min used to maintain sink 
conditions. CSIC was released from the film formulation with a burst effect. Over 80% of drug 
could be detected in the dissolution medium in 60 minutes, (n=3). 
 
 
 
In addition, bioactivity of the film formulated CSIC, including direct antiviral activity 
(EC50-antiviral) and protective effect (EC50-protection), was investigated in P4R5 indicator cells.  
Drug’s antiviral activity was evaluated when the cells were simultaneously incubated with HIV 
and serially diluted CSIC films. Whereas, the protective effect was determined when the cells 
were pretreated with film formulated CSIC and then removed from the cells. According to the 
current study, EC50-antiviral and EC50-protecction of CSIC in the film dosage form were found to be <1 
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nM and <20 nM, respectively (Figure 14).  The antiviral activity of film formulated CSIC was 
similar to that of the API (1.2-5 nM) [128, 132]. Formulating CSIC in a polymeric vaginal film 
thus had no substantial effect on its anti-HIV bioactivity. A comparable finding was also 
reported by Ayman et al showing that formulating DPV in a polymeric vaginal film could 
maintain the drug’s bioactivity [36]. The EC50-antiviral of DPV API and DPV film were determined 
to be 7.9 nM and 8.7 nM respectively using a TZM-bl indicator cell assay [152]. 
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Figure 14 Bioactivity of film formulated CSIC at time zero. 
The bioactivity of film formulated CSIC was investigated in P4R5 HIV infection indicator cells. 
Both direct antiviral activity (with the presence of drug) and protective effect (without the presence 
of drug) were tested.  
 
 
 
Since Lactobacillus play an important role against viral infection in the vagina by 
maintaining acidic pH and producing hydrogen peroxide, it is important to assess the 
compatibility between CSIC film products and Lactobacillus for safety purpose using the 
Standard Microbicide Safety Test. As shown in Table 3, the seven major strains of Lactobacillus 
were unaffected by exposure to the CSIC film formulation. 
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Table 3 Evaluation of CSIC film compatibility with Lactobacillus. 
The positive value indicates increased cell viability. In contrast, negative values illustrate decreased 
cell viability. The loss of viability has to be < 1 log10 to meet the safety requirement. 
 
 
 
 
 
 
 
 
Lactobacillus strain tested Log Difference 
(T30 minute Plate Count – T0 minute Plate 
Count) 
L.crisp ATCC 33197 0.113 
L.jen LBP 28Ab -0.154 
L.jen ATCC 25258 -0.068 
L.crisp ATCC 20225 -0.082 
L.crisp LBP 90Aa -0.143 
L.crisp 6099 -0.100 
L.crisp 2116V -0.023 
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3.3.4 CSIC film stability  
CSIC film stability studies were carried out by storing films in 30°C / 65% RH and 40°C / 75% 
RH environmental chambers. Based on the physicochemical evaluation performed, CSIC films 
were found to be stable at 30°C/65% RH for a period of 12 months, and at least 6 months under 
stressed condition (40°C/75% RH).  Figure 15 and Table 4 show drug content in the films and 
drug dissolution detected at 10 minutes respectively. The drug content obtained at each time 
point was unchanged (± 10%) relative to the drug content at time zero.  Additionally, film 
disintegration was observed within 3 minutes, and the residual water contents in the film 
products were found be to lower than 10% at all the time points. Moreover, bioactivity of CSIC 
could be maintained in the film formulation throughout the stability assessment period. No loss 
of Lactobacillus viability was observed over time, which again confirmed the compatibility 
between CSIC film and the vaginal Lactobacillus.  
 76 
 
 
 
Figure 15 CSIC drug contents results from the stability study.  
CSIC films were stored for 12 months in 30°C/65% RH and 6 months in 40°C/75% RH as per ICH 
guidelines. Data presented as Mean ± SD (n>3) 
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Table 4 Dissolution of CSIC film over the time frame of stability study. 
No change in terms of cumulative drug release at 10 minutes was observed compared with time 
zero. Data presented as mean ± SD (n=3). 
 
 
 30°C/65% 40°C/75% 
1 M 53.7±5.0 55.5±2.0 
2 M 51.9±0.5 44.1±5.4 
3 M 52.9±4.5 57.9±4.4 
6 M 50.1±5.9 53.7±14.4 
9 M 45.1±2.1  
12 M 52.5±8.7  
 
 
 
Taken together, these results have demonstrated the safety property of the film product. 
The stability study showed that CSIC film should have a minimal shelf life of 12 months. The 
stressed temperature/humidity condition had negligible effects on film properties over a period of 
6 months. 
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3.4 DISCUSSION AND CONCLUSION 
Vaginal film formulation is a mixture of drug substances and excipients that are safe for vaginal 
application. In general, the key components in film products include film forming polymers as 
base platforms and plasticizers for improved flexibility. In addition, other excipients could be 
used to achieve different objectives. For instance, in some cases, cosolvents can be utilized to 
improve drug solubility; enhanced film softness could be attained with humectants; and 
disintegrant can be employed to facilitate film disintegration. Polymers with variable mucosal 
adhesion properties might also be used to modulate film residence time on the surface of the 
vaginal mucosa. 
In terms of film forming polymers, numerous polymers can be used, which include 
hydroxyethyl cellulose (HEC), polyvinyl alcohol (PVA), hydroxypropylmethyl cellulose 
(HPMC), poly(vinyl pyrrolidone) (PVP), and Carbopol® [162]. In the current CSIC film 
formulation, PVA and HPMC were selected. PVA was chosen since it is safe for vaginal 
preparations and is the base polymer used in the VCF product. In addition to the film forming 
characteristics, PVA can also be used as a lubricant and a viscosity-increasing agent with 
moderate mucoadhesive properties [162]. The lubrication effect might help improve user 
adherence since it can boost sexual pleasure. The increased viscosity and mucoadhesive function 
will allow the film to stay longer in the vagina which in turn may increase drug concentration in 
the cervicovaginal tissue and lead to an improved efficacy. Other than PVA, another film 
forming polymer HPMC was included. Previous in vitro release studies have shown that the 
utilization of HPMC resulted in an initial burst release of APIs from film formulations [36, 163]. 
The fast drug release, over half of the loaded drug detected in the dissolution medium within one 
hour, could be essential for the development of coitus-dependent regimens. Lastly, these two 
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film-forming polymers provide a hydrophilic matrix, in which drug particles can be uniformly 
distributed. 
Another category of component involved in the CSIC film formulation is the co-solvent. 
Although the lipids, bile salts and BSA are present in the vaginal fluid, which can help dissolve 
CSIC, the majority of the fluid is water which will substantially restrict the amount of drug being 
dissolved [24]. Limited drug solubilization will impact the dissolution rate of CSIC in the vagina. 
Also, drug remaining in the vaginal lumen could be removed rapidly by mucus shedding and 
menses before drug permeation in the tissue. In this regard, co-solvents can be used in the 
formulation to increase drug solubility. In this chapter, a co-solvent system consisting of PEG 
400, propylene glycol, and glycerin was employed for vaginal application.  The three cosolvents 
enhanced water miscibility of CSIC. This increased  miscibility could be due to the hydrogen 
bonding by their hydrophilic regions, and, simultaneously, disruption of water self-association by 
their hydrophobic groups [164]. In addition to the solubilization properties, these three agents 
also improved the flexibility and the manufacturability of the film as plasticizers. Without the 
presence of propylene glycol and glycerin, film products were found to be rigid and curly in 
early stages of investigation. Furthermore, glycerin also acted as a humectant, which absorbed 
moisture and enhanced film softness. Importantly, in addition to these physicochemical 
advantages, the three cosolvents are included in the FDA Inactive Ingredients Database and 
generally considered as safe for vaginal exposure.  
Once all the excipients were chosen, drug-excipient compatibility studies were performed 
prior to film preparation. As film formulation is a solid dosage form, a compatibility study was 
conducted in solid state by monitoring the thermal events of CSIC using DSC. Even though a 
shift of CSIC’s melting point to a lower temperature was observed for the CSIC-glycerin mixture 
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(Figure 11), the drug’s bioactivity study has confirmed that the pharmacological properties of 
CSIC remained unchanged in the presence of glycerin (Figure 14). In conclusion, the results 
confirmed the compatibility between drug substance and the excipients investigated. 
The dosing level of CSIC in the film formulation was determined based on the antiviral 
activity of CSIC (EC50-antiviral of 1 nM) and the dosing level used in DPV vaginal films (1.25 mg). 
Previous studies have shown that the EC50 of CSIC was about 1 nM (0.3 ng/mL). To achieve 
anti-HIV efficacy, it is assumed that the drug concentration in the local cervicovaginal tissue has 
to be 1000 time higher than its EC50. Therefore, approximately 0.3 μg/mL CSIC was required for 
each dose. As the volume of vaginal fluid secreted every day in vaginal lumen is about 1 mL, at 
least 0.3 μg of CSIC has to be formulated in each unit of film. In case of DPV, 1.25 mg DPV 
was originally loaded in a vaginal gel formulation. The gel product was assessed in clinical trials 
and approved to be safe and well tolerated [165, 166]. The same dosing level was later applied in 
a vaginal film formulation (1.25 mg/film), which showed potent anti-HIV bioactivity in TZM-bl 
model and no toxicity to the innate microflora lactobacilli [36]. In light of these considerations, 
approximately 1mg CSIC per film was chosen as the target dose. It is however important to note 
that with the co-solvent system chosen, the current film formulation allow for a much higher 
dose of CSIC if needed [167]. Previous work conducted in our labratory has shown that up to 10 
mg of CSIC can be dissolved and dispersed uniformly in each film unit using the current 
formulation platform.   
To further optimize the film formulation, the amounts of glycerin and propylene glycol 
that could be applied were adjusted according to the characteristics of film products, 
manufacturability, and safety regulations. In terms of safety, previous studies have reported that 
the application of high doses of glycerin and propylene glycol in vagina or rectum resulted in 
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some adverse effects, such as epithelial damage, excessive mucosal fluid secretion and increased 
HIV infection risk [168, 169]. These side effects are mainly caused by the dehydration effect of 
the excipients. When glycerin and propylene glycol are used in high concentrations, the product 
becomes hyperosmotic and tends to absorb solvents from the surrounding tissues. For example, 
in the TFV gel study, when 20% of glycerin was used in the formulation, this high percentage of 
glycerin caused a high product osmolality (3111±10 mmol/kg), which induced epithelial 
stripping [170]. In contrast, when the percentage of glycerin was reduced to 5%, gel’s osmolality 
was reduced to 836 ± 11 mmol/kg and the adverse reaction of epithelial damage was absent. 
Therefore, for safety purposes, the percentages applied for propylene glycol and glycerin in any 
vaginal preparations have to remain low. In the optimized film formulation, the percentages of 
solvent PEG 400, propylene glycol and glycerin were set at 2.5%, 1%, and 0.5% respectively in 
order to avoid potential adverse effects.  
In addition, osmolality of all the products needs to be monitored. Despite osmolality 
applies only to liquid or semi-solid dosage forms, in a biological environment, films will become 
a gel-like product upon contact with vaginal fluid and posse an osmolality.  In the worst case 
scenario in vivo, if the gel-like product cannot be distributed rapidly in the vaginal lumen, local 
solute concentration will increase, which may create a hyperosmotic condition and cause 
toxicity. In order to avoid these potential adverse effects, the percentages of solvent PEG 400, 
propylene glycol, and glycerin in the optimized film formulation were kept low, and set at 2.5%, 
1%, and 0.5% respectively. To confirm the safety properties, film induced osmolality was 
assessed. CSIC film was dissolved in 3 mL vaginal fluid simulant, and tested for osmolality 
using an osmometer. The volume was chosen since it was the minimal volume required to 
completely dissolve a 1” x 2” vaginal film. The resulting data showed that the osmolality of 
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CSIC film was slightly hyperosmotic (334±4.04 mOsm/kg) compared with normal vaginal 
secretions (260-290 mOsm/kg). Nonetheless, compared with the osmolality determined for the 
reduced glycerin TFV gel (<836±11 mmol/kg ), CSIC film product was still considered as a safe 
vaginal product [170] .  
After the film product was prepared, the physicochemical and biological properties of the 
CSIC film were thoroughly investigated. Fast drug release from film formulation was confirmed 
by rapid film disintegration (< 3 minutes) and drug dissolution (< 1h) (Figure 13). About 50% of 
drug being detected in the dissolution medium 10 minutes after film administration indicate a 
burst effect. The burst drug release could be contributed to the presence of detergent PEG 4000 
because it has been reported to accelerate the disintegration and subsequent drug dissolution in a 
fast-release tablets due to its high molecular weight [171].   
Water content retained in the CSIC film product was determined to be less than 10%. 
This amount of water ensured film softness and flexibility, on the other hand, warranted drug 
stability and film attributes over time. In addition, the bioactivity of film formulated CSIC was 
found to be comparable to CSIC API. This result suggests that the presence of target excipients 
and manufacturing procedures such as physical mixing and heating will not have any effect on 
the anti-HIV activity of the drug substance. Once all the favorable film characteristics were 
established, the stability study was carried out at 30°C/65%RH for 12 months and at 
40°C/75%RH for 6 months. The physicochemical characterization performed at different time 
points during the stability study indicates that CSIC film remains stable with insignificant 
changes in its drug content, dissolution, bioactivity, and biocompatibility.  
In conclusion, a co-solvent system consisting of PEG400, propylene glycol and glycerin 
was utilized to disperse CSIC uniformly in a water-soluble film dosage form. Using a solvent 
 83 
cast technique, a thin, soft and flexible CSIC film was manufactured. The film formulation was 
found to be stable physicochemically and biologically for at least 12 months. The developed film 
formulation has potential for use with other hydrophobic drugs. 
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4.0  DEVELOPMENT OF CSIC NANOCRYSTAL FORMULATION FOR HIV 
PREVENTION 
4.1 INTRODUCTION  
Currently, 40% of the new chemical entities (NCEs) generated through drug discovery programs 
are poorly water soluble [48]. Poor solubility usually results in a low dissolution rate and erratic 
absorption at the desired site of action. One approach emerging to overcome these issues is the 
preparation of nanocrystal formulations. Drug nanocrystals are nano-sized pure drug particles 
stabilized by stabilizing agents [162]. When the drug nanocrystals are suspended in liquid 
dispersion media, they are termed as nanosuspensions. Unlike the well-known polymeric 
nanoparticles, the stabilizing agents in nanosuspensions cannot form any carrier structure. 
Therefore, the pure drug particles are not encapsulated in carrier systems.  
Drug nanocrystal formulation presents numerous advantages compared to other 
nanosystems. First of all, this formulation strategy can be applied as a universal approach to 
address formulation issues associated with poorly water soluble drugs. Additionally, nanocrystal 
formulations have been administrated via different routes, such as orally, intravenously, and 
topically for hydrophobic drugs [172-174]. Furthermore, nanocrystal formulations can be 
prepared by manufacturing processes currently used in the pharmaceutical industry. The cost of 
manufacturing is low and it can be easily scaled up.  
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Bottom-up precipitation methods and top-down technologies are the two standard 
approaches used for the production of drug nanocrystals in laboratory and pharmaceutical 
industry settings [175]. Bottom up technologies involve methods of assembly. They all start by 
dissolving drugs in solution, allowing the drug molecules to aggregate into particles with sizes in 
the nano-scale range. Specific technology under this category include micro- or nano-
precipitation/solvent replacement, pharmaceutical hydrosol, and high-gravity controlled 
precipitation [176].  
In comparison, top-down technologies can be classified as disintegrating methods, which 
generate nanosized materials by wet bead/pearl milling (NanoCrystal
®
 techonology) or high 
pressure homogenization (HPH) [177]. These processes have been applied to successfully 
formulate poorly water soluble drugs and bring them to the market, for example, Rapamune® 
(sirolimus), Emed® (aprepitant), Tricor® (fenofibrate), and Megace ES® (megestrol acetate).  
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Recently, a combination of the bottom-up and the top-down approaches have been 
developed to further improve the technology [178]. For instance, the NANOEDGE™ technology 
by Baxter relies on the combination of a micro-precipitation step with a subsequent annealing 
step. This annealing step converts thermodynamically unstable materials into a more stable, well 
oriented lattice structure, and prevent the growth of the precipitated nanocrystals [179]. Another 
example of the combination technology is the smartCrystal® technology owned by Abbott, 
which is a series of combination processes tailor-designed for each specific drug and application 
[180, 181]. Examples of the smartCrystal® technology include H 42 (spray-drying and HPH), H 
69 (cavitation-precipitation and HPH), and H 96 (freeze-drying and HPH) [177, 182]. Using this 
technology, the particle size of the drug crystals can be reduced to smaller than 100nm. This 
reduction in particle size will lead to a significant increase in saturation solubility and extremely 
fast dissolution [182].  
Previously, nanocrystal formulation has been used to prepare a long-acting injectable 
product containing hydrophobic NNRTI rilpivirine (TMC278)[183]. TMC278 nanocrystals with 
a particle sized of 200nm were manufactured by wet milling. After a single injection 
(intramuscularly or subcutaneously), drug released sustainably from the formulation over 3 
months in dogs and 3 weeks in mice.     
In studies described in this chapter, a bottom up technology, nanoprecipitation, was 
applied to prepare a CSIC nanocrystal in order to improve its saturation solubility. 
Physicochemical properties, bioactivity, and stability of the CSIC nanocrystal were thoroughly 
evaluated. In addition, macrophages, as one of the most important target cells for HIV infection, 
have been utilized in the present work to assess the rate of cellular uptake. The mechanism of 
nanocrystal uptake was also studied using a series of pharmacological inhibitors. 
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In this dissertation, CSIC nanocrystals were not intended for active lymph node targeting. 
Instead, the desirable physicochemical properties of the nanocrystals were designed for sufficient 
tissue penetration and drug exposure in the interstitium. Therefore, the migration of the 
nanocrystals from interstitium to the draining lymph nodes was a result of passive delivery. If 
CSIC nanocrystals can get into the lymph nodes, theoretically, they can be internalized by all 
types of antigen presenting cells including macrophages, dendritic cells, langerhans cells, and B 
lymphocytes. Studies using macrophages were first conducted since macrophages are the key 
cells in recognizing micro/nanoparticles, and efficient uptake by macrophages would ensure 
desirable drug delivery outcome [184-186]. Even though macrophage was the only cell line 
being investigated in the present work, further studies using other antigen presenting cell lines, 
especially the dendritic cells (langerhans cells) will be warranted.  
 
4.2 MATERIALS AND METHODS 
4.2.1 Materials  
CSIC was synthesized by Dalton Laboratories (Toronto, ON, Canada) with a purity of >98%. 
CSIC existed in fine powder with molecular weight of 334 g/mol. Hydroxypropyl 
methylcellulose E5 (HPMC E5) was obtained from Dow Chemical Company. Pluronic® F98 
Prill was purchased from BASF. 3mL Thermo Scientific™ Slide-A-Lyzer™ dialysis cassette 
with a molecular weight cut off (MWCO) at 3.5K was purchased from Fisher Scientific for in 
vitro release study. Mouse macrophage cell line J774A.1 was generously provided by Dr. Kerry 
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Empey from the School of Pharmacy, University of Pittsburgh. Lisamine
TM
 Rhodamine B 1,2-
Dihexadecanoly-sn-Glycero-3-phosphoethanolamine, Triethylammonium salt (rDHPE) and 
Vybrant® DiO cell labeling solution were purchased from Invitrogen. Pharmaceutical inhibitor 
mannan, filipin, and chlorpromazine were purchased from Sigma-Aldrich. Pharmaceutical 
inhibitor cytochalasin D, nocodazole, amiloride, and amiloride were obtained from Fisher 
Scientific. Sucrose was purchased from Spectrum.  
 
4.2.2 Methods 
4.2.2.1 CSIC nanosuspension and nanocrystal preparation 
CSIC nanosuspension was manufactured using a nanoprecipitation method named three 
phase nanoparticle engineering technology [30, 187]. 12 mg CSIC was physically mixed with 4.5 
mg surfactant Pluronic® F98 and 75 mg polymer HPMC E5.  The mixture was then completely 
dissolved in organic solution methylene chloride (16mL) and ethanol (8mL). By applying 
nitrogen gas on the top of the solution, the drug and stabilizers (F98 and HPMC E5) were co-
precipitated while solvent evaporation. The sample was then placed in a vacuum oven overnight 
to remove the residual organic solvents. The precipitate was re-hydrated in 15 mL 5% sucrose 
solution (w/v) for 0.5h followed by 1h sonication using probe sonicator. The liquid 
nanosuspension obtained was then lyophilized to obtain solid CSIC nanocrystals.   
 
 89 
4.2.2.2 LC/MS analytical methods 
For the quantification of CSIC, samples were injected into an ultra-high performance 
liquid chromatography (UHPLC) which equipped with a triple quad mass spectrometer and an 
atmospheric pressure chemical ionization probe. CSIC was separated from excipients by Thermo 
Scientific BDS hypersil C8 150x4.6mm column. Mobile phases consisting of A: 5mM 
ammonium formate buffer in 60% acetonitrile and B: 5mM ammonium formate buffer in 80% 
acetonitrile was used at a flow rate of 1mL/minute. A gradient method was programmed to start 
with 100% mobile phase A, and gradually switched to 100% mobile phase B by the end of 1.5 
minutes, maintained at B for 2 minutes, and returned back to mobile phase A for the rest of the 
run till 6 minutes. 20uL of each drug-containing sample was injected, and a negative single 
reaction monitoring (SRM) scan was applied to monitor the ionization pathway of CSIC from 
330 to 290 Dalton.  A standard curve was obtained in the rage of 0.1-500 ng/mL.  
 
4.2.2.3 Physicochemical characterization 
Particle size and surface charge  
Hydrodynamic particle size (Z-average) of CSIC nanocrystals were measured using a 
Malvern Zetasizer Nano ZS (Malvern Instruments, Massachusetts) equipped with a back 
scattering. Nanosuspension or reconstituted nanocrystals were diluted 10 times in deionized 
water for optimal measurements. The diluted samples were loaded in the standard disposable 
“polystyrene” cuvettes for dynamic light scattering (DLS) measurement. All the samples were 
analyzed in triplicate at 20°C. 
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Same instrument was used to determine the surface charge (zeta potential) of CSIC 
nanocrystals. Samples prepared for the DLS measurement were transferred to folded capillary 
cells for charge analysis. At least three measurements were made for each sample. 
 
Drug Content 
The CSIC in the nanosuspension was extracted by 40% acetonitrile. Samples were 
vortexed for 10 minutes, followed by centrifugation at 14,500 rpm (14,100 xg) for 5 minutes 
using a eppendorf MiniSpin® plus centrifuge. Drug presented in the supernatant was determined 
by LC/MS method as described above.  
 
Nanocrystal Morphology by Transmission Electron Microscopy (TEM) 
CSIC nanosuspensions with different concentrations were freshly prepared by 
logarithmic dilution in deionized water. Samples were then placed onto 200-mesh formvar 
carbon-coated copper grids, and negatively stained with 1% uranyl acetate. All images were 
acquired by JEM-1011 TEM (JEOL, Ltd, UK).  
 
Crystalline properties of CSIC nanocrystals by differential scanning calorimetry 
(DSC) 
To confirm the crystalline properties of CSIC in the nanocrystal formulation, DSC 
analysis was performed for CSIC nanocrystals, as well as physical mixture and the co-
precipitates in comparison with free drug CSIC, Pluronic® F98, HPMC E5, and lyophilized 
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cryoprotectant sucrose. As melting points can only be observed for crystalline materials, any 
change to the melting endotherm indicated a transformation of drug CSIC. The thermography 
was obtained using DSC 1 STAR
e
 system (METTLER TOLEDO) by heating samples form 25-
350°C at a rate of 10°C per min with a constant nitrogen purge at 50.0 mL/ minute.  
 
In vitro release 
Drug dissolution studies were performed using Distek dissolution system 2100c equipped 
with Distek syringe pump, Disteck TCS 0200C water bath system and Evolution 4300 
dissolution auto-sampler. Nanosuspension was injected into a Slide-A-Lyzer dialysis cassette 
with a 3.5K MWCO. Phosphate-buffered saline (PBS) at both pH 7.4 and pH 4.2 were prepared 
as dissolution medium in order to investigate drug release profiles at different pHs. Further, as 
vaginal fluid simulant (VFS) is more biorelevant compared to buffered solutions. In vitro drug 
release in VFS was also investigated. In detain, VFS was prepared as previously reported: 3.51 
g/LNaCl, 1.40 g/L KOH, 0.222 g/L Ca(OH)2, 0.018 g/L bovine serum albumin (BSA), 2 g/L 
lactic acid, 1 g/L CH3COOH, 0.16 g/L glycerol, 0.4 g/L urea and 5 g/L glucose [24]. The pH of 
PBS and VFS solutions were adjusted to either 7 or 4.2 by adding 0.1N NaOH or HCL.   
Cremophor® RH 40 was added to the dissolution media at a final concentration of 0.1% to 
increase the solubility of CSIC. Additionally, a volume of 500 mL dissolution medium was used 
to maintain a sink condition. Samples were collected at 0.5, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, and 
120 h. Drug contents in each sample were determined by the developed LC/MS method.  
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4.2.2.4 In vitro bioactivity 
Direct antiviral activity was carried out using P4R5 indicator cells. P4R5 cells express the 
gene sequence of receptor CD4, co-receptors CCR5 and CXCR4, and β-galactosidase reporter. 
To test the direct anti-HIV activity of CSIC nanocrystals, P4R5 cells were incubated 
simultaneously with HIV-1 p24 and serially diluted CSIC nanosuspension for 48h.  Afterward, 
the extent of HIV infection was determined using a single replication cycle assay as previously 
described [188].  
 
4.2.2.5 Stability studies 
Stability studies of CSIC nanocrystal in terms of particle size were performed in both 
liquid and solid forms. In the liquid state, freshly prepared nanosuspension was stored at ambient 
temperature for 7 days. Prior to size analysis, the nanosuspension was vortexed for 5 seconds to 
re-suspend the contents. To test its stability in the solid state, the nanosuspension was 
immediately lyophilized following preparation to remove water. At the end of 1 month, 2 
months, and 5 months, the solid nanocrystals were reconstituted and diluted in water as described 
in section 4.2.2.3. Particle size was then determined by dynamic light scattering (DLS) using a 
Malvern Zetasizer Nano ZS.   
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4.2.2.6 Mechanism of cellular uptake of CSIC nanocrystals by macrophages  
The involvement of energy dependent pathways 
As the application of a much lower temperature (4°C) has been reported to block energy 
dependent processes such as endocytosis [189], an uptake study was performed at both 4°C and 
37°C to investigate their involvement during the process of nanocrystal intracellular uptake. 
Mouse macrophage-like J774.A cells were seeded in 12 well plates at a density of 1.5x10
5
 
cell/mL. Cells were cultured overnight to achieve a 50% confluence. On day 2, macrophages 
were treated with CSIC nanosuspension (5μg/mL, 2ml) and placed in either a cell culture 
incubator (37°C) or a refrigerator (4°C). At 5, 15, 30, and 60 minutes, the drug containing 
solution was removed from cells. Cells were then lysed using 1% Triton in PBS, physically 
scraped from the plates, and stored at -20°C for future analysis. The CSIC that was internalized 
by macrophages was quantified by LC/MS. The amount of cellular protein presented in each 
well was determined by BCA protein assay in order to normalize the drug uptake. Similar studies 
were also conducted for the free drug. 0.1% DMSO was utilized to disperse the hydrophobic 
CSIC in aqueous cell culture medium. 
 
Mechanism study using pharmacological inhibitors 
The uptake mechanism for CSIC nanocrystals was investigated using various 
pharmacological inhibitors which include: phagocytosis pathway inhibitor mannan (200 μg/mL) 
and cytochalasin D (10 μg/mL); clathrin dependent pathway inhibitor sucrose (150 mg/mL), 
chlorpromazine HCL (10 μg/mL) and nocodazole (10 μg/mL); caveolae dependent pathway 
inhibitor filipin (1 μg/mL); and micropinocytosis pathway inhibitor amiloride (100 μg/mL). 
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Specifically, cells were pretreated with each inhibitor for 0.5-1h. Subsequently, the inhibitors 
were replaced by 5 μg/mL CSIC nanosuspension (200 µL) and cultured for 1h. Cells were then 
washed by PBS and lysed for drug content analysis. The amount of cellular protein in each well 
was also determined as described above in order to normalize the drug uptake.  It is important to 
note that the concentration and incubation time applied for each inhibitor were pre-determined to 
assure ≥70% cell viability. Adjustments were made as needed.   
 
4.2.2.7 Cell imaging 
Transmission electron microscopy (TEM)  
To confirm the internalization of drug nanocrystal by J774A.1 cells, cells were first 
incubated with CSIC nanosuspension (5μg/mL) for 1h. The cells were then washed by PBS and 
fixed in cold 2.5% glutaraldehyde in 0.1M PBS. After being rinsed, cells were fixed in 1% 
Osmium Tetroxide with 1% potassium ferricyanide. Subsequently, cells were rinsed again in 
PBS, dehydrated through a graded series of ethanol, and embedded in Epon. Semi-thin (300 nm) 
sections were cut on a Reichart Ultracut, stained with 0.5% Toluidine Blue and examined under 
light microscope. Then, ultrathin sections (65 nm) were cut, and stained with uranyl acetate and 
Reynold’s lead citrate. Sections were examined on Jeol 1011 TEM. 
 
Live cell imaging by confocal microscope 
To visualize the cellular uptake of CSIC nanocrystals, this nanomaterial was labeled with 
a red fluorescent dye rDHPE, while, and the viable macrophages were labeled with a green 
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fluorescent probe Vybrant
®
 Dio cell-labeling solution [150]. The CSIC/rDHPE hybrid 
nanocrystals were prepared by mixing the dye with the drug and the stabilizers prior to 
dissolving in the organic solvents. J774A.1 macrophages were incubated with Vybrant
®
 Dio 
solution (0.5%, v/v) in DMEM for 20 minutes. Afterward, the staining medium was removed, 
and the cells were washed by fresh, warm DMEM three times (10 minutes for each wash). Then, 
specimen was placed under a confocal microscope. Images of planes at various depths within the 
cells (0.5 µm per step) were collected as baseline for 3-D reconstitution. Subsequently, 
CSIC/rDHPE hybrid nanocrystals were applied. More optical images of the cells were captured 
every 2 minutes for the first 1h, and every 5 minutes for the following 3h using a Nikon A1 
confocal microscope, 488 nm (Vybrant
®
 Dio) and 562 nm (rDHPE) laser excitations, and a 60x 
objective.  
 
4.2.2.8 Statistical analysis 
All results were presented as the mean ± standard deviation (SD). Pairwise differences 
were determined by Student’s t test. A p value <0.05 was considered statistically significant. 
Two-way ANOVA with Bonferroni test was applied for in vitro release study since two 
independent variables time and dissolution medium were involved (GraphPad Prism 5).  
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4.3 RESULTS 
4.3.1 Physicochemical characterization 
The nanocrystal particle size (Z-average) weighted by intensity was determined to be  243 nm. 
The Polydispersity Index (PdI) of the sample was less than 0.3 (Figure 16), which indicates a 
narrow size distribution in the CSIC nanocrystal formulation. As shown in the graph, the sample 
was monomodal with only one peak.  Additionally, CSIC nanocrystals were slightly charged at -
7.8mV. Drug concentration in the CSIC nanosuspension sample was analyzed by LC/MS and 
quantified to be 0.8 mg/mL.  
The crystal morphology of CSIC nanocrystals was also observed under TEM (Figure 17). 
CSIC nanocrystals resembled long rods with smooth edges, which were quite similar to that of 
free drug substance described in chapter 2 (Figure 6). Upon series dilution, no change was 
observed in the morphology of the nanocrystals. 
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Figure 16 Particle size distribution of CSIC nanocrystals determined by dynamic light scattering. 
Particle size distribution was presented by intensity.  
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Figure 17 The morphology of CSIC nanocrystal observed under TEM. 
CSIC nanocrystals resembled long rods with smooth edges. The morphology of the nanocrystals 
was quite similar to that of free drug substance. Upon series dilution, no change was observed in the 
morphology of the nanocrystals. 
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The crystalline property of CSIC within each stage of preparation was monitored by its 
thermal behavior (Figure 18). It was found that the melting point of CSIC was observed at 252 
°C in the physical mixture, while, no endothermic peak for the drug substance was detected for 
the co-precipitate sample. This change indicated that CSIC formed amorphous precipitates with 
the stabilizers during the process of rapid solvent evaporation. More interestingly, the missing 
melting peak of CSIC re-emerged in the final nanocrystal products (278 °C) when the co-
precipitates were hydrated in the aqueous solution which suggested the recrystallization of the 
drug during the process of probe sonication.  
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Figure 18 Thermal behaviors of each stabilizer, drug CSIC, drug/stabilizer physical mixture, 
drug/stabilizer co-precipitate, lyophilized sucrose and CSIC nanocrystals.   
Thermal behaviors were assessed by DSC. Samples were heated from 25-350 °C at a rate of 10°C 
per min. The results have shown that the melting points of CSIC remained unchanged for the 
physical mixture, but disappeared for the co-precipitate sample. The missing melting peak of CSIC 
re-emerged in the final nanocrystal products (278 °C) when the co-precipitates were hydrated in 
the aqueous solution.  
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In vitro drug release studies were conducted in both PBS (pH 7.4) and VFS (pH 4.2) 
using a USP-I Distex instrument. CSIC was released continuously from the nanocrystal 
formulation in a linear fashion for 96 h (Figure 19).  Approximately 90% of the drug was 
recovered by the end of the experiment. A zero order kinetics model can be used to describe this 
release profile with a dissolution rate of 0.11 µg/min (R
2
 > 0.97). Even though the percentage of 
drug release from CSIC nanocrystals in PBS dissolution medium was found to be higher than the 
corresponding ones in the VFS dissolution medium at 36h and 72h (p<0.05), the overall trends of 
release in these two dissolution media are very similar. 
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Figure 19 In vitro release profiles of CSIC from CSIC nanocrystal formulation in vaginal fluid 
simulant (VFS, pH 4.2) and phosphage-buffered saline (PBS, pH 7.4) respectively. Dissolution study 
was conducted using Distek dissolution system 2100c equipped with Distek syringe pump, Disteck 
TCS 0200C water bath system and Evolution 4300 dissolution auto-sampler. Nanosuspension was 
injected into a Slide-A-Lyzer dialysis cassette with a 3.5K MWCO. At 36h and 72h, the percentage 
of drug release from CSIC nanocrystals in the PBS group was significantly higher than the VFS 
group (Two-way ANOVA, Bonferroni test, *p<0.05, **p< 0.001) (n=3). 
 
 
 
 
4.3.2 In vitro bioactivity study 
In the bioactivity study, P4R5 HIV indicator cells were treated with CSIC nanosuspension or 
CSIC API at various concentrations.  Drug concentration versus HIV survival percentage 
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profiles were plotted for both test articles. The bioactivity of CSIC nanocrystals was found to be 
identical to that of the free drug substance (Figure 20) and caculated to be 1nM. This result 
suggests a limited effect of  the stabilizers and the nanotechnology on CSIC’s bioactivity.  
 
 
 
 
 
 
Figure 20 Antiviral activity of CSIC nanocrystals compared to the free drug substance. 
HIV was incubated with CSIC free drug or CSIC nanocrystals at different concentrations. After 
48h of incubation, the infectivity of HIV-1 was determined using a single replication cycle assay. The 
inhibition effect of CSIC nanocrystals was determined to be identical to that of free drug substance. (n=1) 
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4.3.3 Stability study 
In the stability studies, particle size of the nanosuspension/ nanocrystals was monitored over time 
in both lipid and solid form. In the liquid state, the particle size was found to be stable for at least 
7 days. After lyophilization, particle size of the solid CSIC nanocrystals is stable for a period of 
5 months in a desiccator at room temperature.  In all cases, particle sizes were maintained at 230 
nm with a narrow size distribution (PdI <0.3) (Table 5).   
 
 
 
Table 5 Stability of CSIC nanocrystals in both liquid and solid states. 
The particle sizes of CSIC nanocrystals in liquid and solid states were monitored for 7 days and 5 
months respectively. (n=3) 
 
 
 
 
Time points  Z-Average, nm PdI 
In liquid state 
T0 217.0±6.9 0.24 
7 days 238.0±2.4 0.22 
In solid state 
T0 227.9±0.2 0.22 
1M 232.0±2.4 0.22 
2M  233.0±2.6 0.24 
5M  244.6±1.4 0.22 
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4.3.4 Intracellular uptake by macrophage cell line J774A.1 
It is well known that low temperature (4˚C) can block the energy dependent pathways involved 
in endocytosis. By comparing the uptake profiles of test articles at 37°C and 4°C, the existence 
of energy dependent endocytosis during the process of intracellular uptake can be determined. In 
the case of CSIC nanocrystal, its cellular internalization uptake was significantly inhibited by the 
low temperature (4°C) compared with the physiological temperature (37°C), especially at earlier 
time points. Five minutes after drug exposure, the amount of CSIC nanocrystal internalized at 
4°C was only 42.4% of that at 37°C (Figure 21a). In contrast, the amounts of free drug 
internalized at 4°C at 5 minutes accounted for about 80% of the drug internalized at 37°C 
((Figure 21b). These results thus indicated the involvement of energy dependent pathways while 
the intracellular uptake of CSIC nanocrystals. As lower temperature could also decrease the 
diffusion coefficient, most likely the free drug molecules entered the macrophage via simple 
diffusion. The reduction in API’s uptake was a result of a decreased diffusion coefficient at 
lower temperature. 
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(a) 
  
(b) 
 
 
 
Figure 21 The intracellular uptake of nanocrystal and free drug substance at 37°C and 4°C for a 
period of 1h. 
Intracellular uptake of (a) CSIC nanocrystals and (b) free drug. Uptake was reported as ug of 
CSIC per mg of total cell protein. The amount of cellular protein presented in each well was determined 
by BCA protein assay in order to normalize the drug uptake. Pairwise differences were determined by 
Student’s t test. A p value <0.05 was considered statistically significant. * denotes significant difference 
(p<0.05) when comparing the amount of cell uptake at 37°C to 4°C. (n=6) 
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To further understand the mechanism of nanocrystal uptake by J774A.1 cells, seven 
pharmacological inhibitors were applied individually to block specific endocytosis pathways 
prior to drug exposure. Any diminution of nanocrystal internalization after certain treatment 
reflected the involvement of the typical pathway targeted by that inhibitor [190] .  
Mannan and cytochalasin D are the inhibitors specific for phagocytosis pathway. Mannan 
competes with the test articles on mannose receptors expressed on the surface of antigen 
presenting cells such as macrophages and dendritic cells. Cytochalasin D disrupt the F-actin 
filaments necessary for phagocytosis [191]. As shown in Figure 22, the use of these two 
inhibitors did not reduce the uptake of nanocrystal. This result might suggest that the 
phagocytosis pathway is not involved in the process of nanocrystal internalization.  
In addition, sucrose, chlorpromazine, and nocodazole, all clathrin mediated inhibitors, 
were also evaluated for uptake pathways. Sucrose induces hypertonicity, which prevents the 
assembly of clathrin-coated pits [192]. Chlorpromazine inhibits the formation and budding of 
clathrin-coated pits [193]. Nocodazole inhibits endosome-lysosome trafficking by interfering 
with the microtubule network causing microtubule depolymerization. 
In the cellular uptake mechanism study, sucrose (150mg/mL), a pharmacological 
inhibitor for clathrin mediated endocytosis, was found to reduce the cellular uptake of CSIC 
nanocrystals substantially. Nonetheless, the inhibition effect of sucrose might be complicated by 
the fact that sucrose (50mg/mL) was used in the CSIC nanocrystal formulation as a 
cryoprotectant. Thus, other clathrin mediated inhibitors have to be investigated as well. The 
result has shown that the uptake of CSIC nanocrystals was also impeded by another two clathrin 
mediated inhibitors chlorpromazine and nocodazole. Taken together, we can conclude that 
clathrin-mediated endocytosis was actively involved in the process of cell uptake. 
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Moreover, filipin, which perturbs cholesterol functions, was also applied to inhibit the 
caveolae-mediated pathway [194]. However, after its treatment, no significant effect on 
nanocrystal uptake was observed, revealing a caveolae-independent process.   
Furthermore, macropinocytosis inhibitor amiloride which impede the function of Na+/H+ 
exchange protein was tested [193]. The application of this inhibitor had no impact on the extent 
of internalization. Thus, macropinocytosis was not involved in the cellular uptake of nanocrystals 
either. Overall, these results indicated that the uptake of CSIC nanocrystal is mediated 
predominately by clathrin-mediated endocytosis, at least in the J774A.1 cells (Figure 22).  
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Figure 22 The impact of pharmaceutical inhibitors on cellular uptake of CSIC nanocrystals in 
macrophage cell line J774A.1. 
Various pharmacological inhibitors were applied to investigate the mechanism of nanocrystal cellular uptake: 
phagocytosis pathway inhibitor mannan (200 μg/mL) and cytochalasin D (10 μg/mL); clathrin dependent 
pathway inhibitor sucrose (150 mg/mL), chlorpromazine HCL (10 μg/mL) and nocodazole (10 μg/mL); 
caveolae dependent pathway inhibitor filipin (1 μg/mL); and micropinocytosis pathway inhibitor amiloride 
(100 μg/mL). Macrophages were pretreated with each inhibitor for 0.5-1h. Subsequently, the inhibitors were 
replaced by 5 μg/mL CSIC nanosuspension (200 µL) and cultured for 1h. Cells were then washed by PBS and 
lysed for drug content analysis. The amount of cellular protein in each well was also determined as described 
above in order to normalize the drug uptake.  Pretreatment with clathrin mediated inhibitors sucrose, 
chlorpromazine, and nocodazole inhibited the uptake of CSIC nanocrystals in J774A.1 cells 
compared with the control group with no inhibitor intervention. 
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4.3.5 Cell based imaging 
In the imaging studies, both TEM and confocal microscopes were utilized to confirm the 
internalization of CSIC nanocrystal by macrophages. In Figure 23, CSIC nanocrystal determined 
by TEM was outlined in a red rectangle. Drug nanocrystal was present in the cytoplasm of the 
macrophage with a particle size of 250 nm. A similar finding was obtained by confocal 
microscopy in a real time fashion using rDHPE/CSIC hybrid nanocrystals. As shown in Figure 
24, 15 minutes after drug exposure, nanocrystal uptake could be easily observed. CSIC 
nanocrystals first accumulated on the surface of the cell membranes presented as a round circle. 
Afterwards, drug nanocrystals penetrated the cytoplasm and merged with the cytoplasm marker 
Vybrant® Dio. 
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Figure 23 Cellular uptake of CSIC nanocrystals by TEM. 
Drug nanocrystals could be readily identified by shape as outlined in red. Cell samples were 
embedded in Epon and cut into ultrathin sections (65 nm). Sections were then stained with uranyl 
acetate and Reynold’s lead citrate, and examined on Jeol 1011 TEM. 
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Figure 24 Cellular uptake of rDHPE/CSIC hybrid nanocrystals over a period of 4h. 
Live cells were labled in green using a green fluorescent probe Vybrant® Dio cell-labeling solution 
and rDHPE/CSIC hybrid nanocrystals were presented in red.The images in the top panel were 
collected from one optical section at different time points, and the bottom ones were the 
reconstructed 3-D model from the Z-stacks. Images of the cells were captured every 2 minutes for 
the first 1h, and every 5 minutes for the following 3h using a Nikon A1 confocal microscope, 488 nm 
(Vybrant® Dio) and 562 nm (rDHPE) laser excitations, and a 60x objective.  
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4.4 DISCUSSION AND CONCLUSION 
During the process of nanocrystal formulation development, the biggest challenges were the 
choice of the right stabilizers and the appropriate concentrations. In general, a desirable stabilizer 
needs to be amphiphilic. The hydrophobic segments can interact with hydrophobic drugs via 
hydrophobic interactions, while the hydrophilic segments can interact with the aqueous medium 
via hydrogen bonding. To date, stabilizers that have been successfully employed in nanocrystal 
formulations include the polymers HPMC, PVA, and HPC, and the surfactants Pluronics and 
sodium lauryl sulfate. In the current study, the class of Pluronics was chosen since  it has been 
previously used to stabilize paclitaxel nanocrystals which was manufactured by the same method 
as CSIC nanocrystals [195]. In addition, as Pluronics are hydrophilic and neutral charged, these 
properties can help reduce their surface interactions with the hydrophobic or negatively charged 
segments in cervicovaginal mucin structures. As a consequence, the application of Pluronics 
could facilitate drug penetration through human cervicovaginal mucus [61, 196]. Furthermore, 
Pluronics are triblock copolymers composed of a hydrophobic poly(propylene oxide) (PPO) 
chain in the center and flanked by two uncharged hydrophilic PEG chains. When the molecular 
weight of the hydrophobic segment PPO is higher than 3 kDa [196], the large section of PPO 
will allow sufficient interactions with hydrophobic drug CSIC and stabilize the nanocrystal 
system sufficiently. In light of these findings, among many Pluronics, Pluronic F127, F108 and 
F98 were selected as candidates for the formulation development [196].  
The concentrations of Pluronic were determined according to their critical micelle 
concentrations (CMCs). When the concentration goes beyond its CMC, the amount of surfactant 
monomers adsorbed on the surface of nanocrystals will be substantially reduced due to micelle 
formation. Thus, the concentration of the residual monomers that can physically separate the 
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nanocrystals will be much less than what we expect, making the nanocrystals prone to 
aggregation. According to the data provided by the manufacturer, the CMC of F127, F108 and 
F98 at 37°C are 0.011mg/mL, 0.012 mg/mL, and 0.36 mg/mL respectively. Therefore, Pluronic 
F98 at a concentration of ≤0.36 mg/mL was applied in this study.   
Furthermore, from the stand point of lymph node drug delivery, the application of 
Pluronics can also reduce the non-specific interactions between the particle surface and the 
interstitium as shown by improved lymphatic uptake [197-199]. More importantly, this surface 
coating would not decrease drug retention in the lymph nodes [200].  
To further stabilize CSIC nanocrystals and prevent them from agglomeration, another 
stabilizer was warranted. HPMC was selected in the current formulation since it is safe for 
vaginal drug application and it has been commonly used as a stabilizing agent or suspending 
agent. In addition, it has been reported that increased hydrophobicity of a stabilizer is correlated 
to a decreased tendency of nanoparticle aggregation [201]. Thus, among the HPMC family, 
HPMC E5 with a relatively high hydrophobicity (higher percentage hydrophobic methoxyl 
groups) was chosen to hinder the nanocrystal growth. 
The size of the CSIC nanocrystal was set to be in the range between 200 and 500nm since 
it was ideal for vaginal drug delivery according to previous literatures [39, 202]. This size range 
would allow for sufficient drug loading even though much smaller nanoparticles (20-40 nm) 
could be internalized by the epithelial cells in  the FRT efficiently and detected in the draining 
lymph nodes within one hour when administered vaginally [106].  Hanes et al. also reported that, 
compared with the 100nm nanoparticles, the larger ones (200nm and 500nm)  with a dense 
surface coating by polyethylene glycol (PEG) could traverse the cervicovaginal mucus more 
efficiently [203]. In the current study, the target particle size of CSIC nanocrystals was achieved 
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by adjusting the time of probe sonication during the process of manufacturing. As confirmed by 
DLS (Figure 16) and TEM (Figure 17), it can be concluded that CSIC nanocrystals can be 
prepared with an optimal particle size using the current processing method. After preparation, 
sucrose was used as a cryopreservative to maintain the nanocrystal size during lyophilization. 
Based on the particle size determined by DLS (243 nm) and TEM, it can be concluded that CSIC 
nanocrystals can be prepared with an optimal particle size using the current processing method. 
In addition, the prepared CSIC nanocrystals featured a slightly negative charge which 
may benefit vaginal drug delivery and lymphatic targeting. Since cervicovaginal mucus and 
interstitium are both negatively charged [204-206], the anionic nanocrystals might transport 
more rapidly in the mucus and drain well from the interstitial space due to electrostatic repulsion 
[94, 107].  
The melting point of CSIC in the nanocrystal formulation was tested by DSC and was 
found to be similar to that of free drug (Figure 18). The preservation of drug crystal property 
could be beneficial since crystal structure is generally more stable compared to the amorphous 
forms.  
The sustained release of CSIC from nanocrystals (Figure 19) suggests that drug 
nanocrystals act as a saturated drug reservoir, whereas, the stabilizers act as a semipermeable 
membrane maintaining a constant concentration gradient [207]. This finding is in line with a 
previous study in which a paclitaxel nanocrystal formulation was manufactured using the same 
preparation method as CSIC, and paclitaxel was released in a sustained manner from the 
nanocrystal formulation for over 72h  [208].  
To gain insights into whether nanocrystal technology can preserve or benefit the ability 
of CSIC to prevent HIV associated cell infection, the antiretroviral bioactivity of CSIC 
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nanocrystal was investigated. The result showed the high potency of CSIC in the nanocrystal 
formulation presenting an EC50 value at the same nanomolar level as free drug (1 nM, Figure 
20). Formulating CSIC into a nanocrystal formulation did not hinder drug interaction with the 
cell membrane and its diffusion into the cells for enzyme binding.  
Other than the physicochemical properties, intracellular uptake of the CSIC nanocrystal 
by macrophages was also explored and compared with CSIC API. Primary studies showed that 
both CSIC nanocrystals and the free drug could be readily internalized by macrophages. 
However, despite statistical analysis revealing that there is no significant difference between 
these two test articles, there was a trend for better uptake with free drug (Figure 21), which was 
unexpected. To better explain these results, comprehensive mechanism studies were conducted. 
By performing an uptake study at lower temperature (4°C), it was found that an energy 
dependent pathway was involved in the process of nanocrystal uptake but not for the free drug. 
The following study using the pharmacological inhibitors further proved that the clathrin-
dependent endocytosis as the main pathway for the uptake of CSIC nanocrystals. In this regard, 
the application of cryoprotectant sucrose, a clathrin dependent inhibitor, might result in a 
reduced nanocrystal uptake even though the concentration of use (50mg/mL) in the formulation 
was only one third compared to that employed as an inhibitor (150mg/mL).  
Another interpretation for the limited nanocrystal uptake could be described as 
orientation dependent particle recognition. A previous study has shown that the internalization of 
elliptical disk shaped particles (long 3-14μm, aspect ratio 2-4, thickness 400-1000nm) was 
highly dependent on the local particle shape at the point of initial contact on cells [209]. 
Specifically, when the cells approached along the major axis of the elliptical particles, the cell 
membrane showed marked progression on the particles. In contrast, if the cell contacted the flat/ 
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long side of the particles initially, no engulfment would occur. In this regard, as CSIC 
nanocrystals possess a long rod shape that is similar to the elliptical dish, the reduced 
macrophage uptake could be explained by the undesirable angle of contact between nanocrystals 
and macrophages.  
In addition, the utilization of Pluronic F98, a PEG containing stabilizer, might also 
impede the uptake of CSIC nanocrystals. To date, no study has investigated the effect of 
Pluronics as a stabilizer on nanocrystal uptake by macrophages. However, the presence of 
stabilizer (Pluronic®) on the surface of nanocrystals might play a similar role as the surface 
modifier Pluronic® employed in nanocarrier systems such as liposomes [210, 211]. In these 
nanocarrier systems, surface modification by PEG or Pluronics® has been utilized to prevent the 
polymeric nanoparticles from recognition and uptake by phagocytic cells [209]. Moreover, a 
higher PEG density would result in a less amount of cell uptake. Therefore, the application of 
Pluronic® in the CSIC nanocrystal formulation may also suppress nanocrystal recognition by 
macrophages and result in a decrease of drug uptake.  
In the cellular uptake mechanism study, it was surprising that the application of 
phagocytosis pathway inhibitor mannan and cytochalasin D did not curb the intracellular uptake 
of CSIC nanocrystals. As the inhibitor concentrations and incubation times employed in the 
current investigation were determined according to previous literatures, these conditions might 
not be optimal for macrophage cell line J774A.1. Further experiments are warrant to rule out or 
confirm the involvement of phagocytosis pathway by using different experimental setting such as 
higher treating concentrations or longer incubation times.  
To better visualize the localization of nanocrystals in cells, live cell imaging was 
conducted by confocal microscopy. Theoretically, Vybrant DiO solution is a cell membrane 
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marker which can be employed to outline the shape of the cell membrane. Once applied, 
however, the cell membrane marker entered into the macrophages rapidly prior to drug exposure 
and worked as a “cytoplasm marker”. To overcome this barrier and confirm the intracellular 
uptake of CSIC nanocrystal, optical sections from cell specimens at specific plane of focus were 
collected. Nanocrystals were found to accumulate on the surface of the cell membrane presented 
as a round circle at the earlier time points, whereas the drug nanocrystals internalized were 
merged with the “cytoplasm marker” as shown at the later time points in Figure 24.  
In the same imaging study, fluorescent dye phospholipid rDHPE was applied to trace the 
movement of CSIC nanocrystal. Because of its hydrophobicity, it was assumed that this dye is 
entangled with the hydrophobic segments of the stabilizers and, therefore, was in close contact 
with the CSIC nanocrystals. As the amount of tracer added was quite low, the use of rDHPE 
should have limited impact on the particle size, polydispersity, surface charge, and morphology 
of the CSIC nanocrystals. In addition, Kabanov’s group has reported that the application of 
rDHPE as a tracer in nanocrystal formulation had no effect on drug uptake and in vitro drug 
release [212]. Overall, this is a promising approach to investigate the cellular uptake of CSIC 
nanocrystals. 
In conclusion, a CSIC nanocrystal formulation was prepared by a nanoprecipitation 
method for vaginal administration. Drug nanocrystals were stabilized in aqueous solution using 
the surfactant Pluronic F98 and the polymer HPMC E5 with a particle size of 240nm and a near 
neutral surface charge. Drug released from the nanocrystals occurred in a controlled manner with 
no burst effect. Even though the CSIC nanocrystal formulation did not seem to increase the 
extent of drug uptake compared with free drug, it has been confirmed that CSIC nanocrystal 
might be rapidly internalized by macrophages via clathrin mediated endocytosis.  
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5.0  VAGINAL DRUG PERMEATION AND LYMPH NODE DRUG DELIVERY OF 
CSIC NANOCRYSTALS 
5.1 INTRODUCTION 
As discussed in Chapter 1, drug concentration in the cervicovaginal tissue is directly associated 
with anti-HIV efficacy after intravaginal administration. Therefore, it is critical to increase the 
drug exposure in the target tissue. In the last decade, nanocrystal technology has attracted great 
attention and has been applied in the field of transdermal and mucosal drug delivery since it has 
been reported to improve tissue penetration and retention [174, 177, 213, 214]. These favorable 
properties of nanocrystals are achieved through increased saturation solubility and larger 
concentration gradients at the site of biological barriers and membranes. In addition, nanocrystals 
exhibit increased bio-adhesiveness due to their large surface area [215].  
Recently, hydrophobic antioxidants rutin and hesperidin were formulated as nanocrystals 
for dermal applications [213, 216]. The antioxidative capacity of the rutin nanocrystal 
formulation was investigated in vivo and compared to that of a water soluble rutin derivative, 
rutin-glucoside [217]. Interestingly, although the concentration of the dissolved rutin in the rutin-
glucoside formulation (5%, w/w) was 500 times higher than that of the rutin nanocrystals 
(0.01%, w/w), drug bioactivity of the rutin nanocrystals was two times as much as the rutin-
glucoside formulation, 59% versus 27%. This finding could be explained by the hydrophobicity 
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of the drug rutin, since hydrophobic molecules generally exhibit better penetration properties 
than hydrophilic molecules. Although glucosidation improved the drug’s water solubility, it 
compromised its ability to penetrate tissue. In comparison, the rutin nanocrystals provided a 
supersaturated solution and an increased concentration gradient on the surface of tissue. The 
hydrophobicity of the drug molecule was also preserved in the form of a nano-sized pure drug 
particle, allowing sufficient drug permeation. Furthermore, the hydrophobic rutin has a higher 
affinity to the binding site in cells than the hydrophilic glucoside (Figure 25).  
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Figure 25 Mechanism of action for the enhanced dermal bioactivity of rutin nanocrystals. 
Compared with rutin glycoside, rutin nanocrystals possess enhanced penetration properties 
because rutin is a hydrophobic molecule with high affinity to the binding site, even though its 
dissolved concentration is 500 times lower than that of the hydrophilic rutin glycoside.  
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In light of these findings, the CSIC nanocrystal formulation prepared in the Chapter 4 
should display a favorable drug permeation property in the cervicovaginal tissue. This chapter 
will describe ex vivo tissue permeability studies and an in vivo pharmacokinetic study in mice 
that were performed to confirm this hypothesis. Tissue permeability studies were conducted with 
excised human cervical tissue. Excised human tissue features complete cell structures including 
epithelial, connective and immune cells [218, 219]. Human cervicovaginal tissue is commonly 
used in the field of microbicide to evaluate the permeation properties of antiretroviral drugs after 
vaginal administration [39, 155, 220]. In the current study, a flow-through diffusion system, in-
line cell, was employed to study permeation of the hydrophobic drug CSIC (Figure 26). This 
diffusion system uses a perfusion fluid below the tissue surface to collect the permeating 
substance in the receptor chamber, which in turn helps maintain sink conditions throughout the 
experiment.  
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Figure 26 In-line cell for tissue permeability study.  
In the current study, membrane was replaced by the explanted human cervicovaginal epithelium. 
CSIC nanocrystals or free drug were dispersed in DMEM and loaded in the donor chamber. 
Receptor medium was infused from the receptor input and collected from the receptor output by an 
autosampler.   
 
 
 
An in vivo animal study was performed to gain insight into the permeation and 
biodistribution of CSIC nanocrystals after intravaginal instillation, especially their migration to 
genital lymph nodes. Genital lymph nodes play a critical role in the early stages of HIV-1 
acquisition. Thus, it is beneficial to deliver drugs to both lymph nodes and cervicovaginal tissue 
in order to achieve improved drug efficacy. Through evaluation of drug distribution in vivo, 
evidence can be generated to confirm our hypothesis that improved tissue penetration can 
facilitate lymphatic trafficking. Previously, Dr. Byron Ballou’s laboratory demonstrated the 
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migration of quantum dots (Qdots) from vaginal lumen to lumbar lymph nodes [105]. The same 
animal model which was used in that study was applied in this dissertation to investigate the 
pharmacokinetic profile of CSIC nanocrystals.   
Prior to drug permeation in the tissue, cervicovaginal mucus is the first barrier following 
intravaginal administration. To target the underlying mucosal tissue, drug particles, either pure 
drug aggregates or drug containing nanoparticles, must first diffuse through the unstirred 
adherent layer of mucus. Previous study has points that drug nanocrystal with specific 
composition could facilitate drug particle transport in mucus [221]. Two mechanisms can 
contribute to the inhibition of particle diffusion across this mucus layer [222, 223]. The first is 
the interaction between particles and mucin induced by electrostatic and/or hydrophobic forces. 
Mucin is a group of highly glycosylated proteins. It is negatively charged because of the high 
content of sialic acid and sulfate [224]. The negative charge of mucin can attract positively 
charged nanoparticles via electrostatic force. In addition, mucins that exist in the ectocervical 
and vaginal epithelia contain some hydrophobic domains (lipid-coated, nonglycosylated, 
cysteine-rich domains), which can anchor lipophilic drug particles [225-227]. This hydrophobic 
interaction will hinder the movement of drug particles in mucus. The second mechanism is the 
size filtering effect due to the limited mesh spacing between the mucin fibers (340±70 nm) [227]. 
In Chapter 4, a CSIC nanocrystal formulation with particle size about 243nm and negatively 
charged surface was designed and prepared for rapid mucus penetration. The goal for this 
chapter was to verify this mucus penetration property by investigating the interaction between 
mucin and CSIC nanocrystals. 
Plasma protein adsorption is commonly investigated for intravenously injected drugs. 
Although for this study CSIC nanocrystals were instilled intravaginally instead of intravenously, 
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it is still imperative to evaluate their plasma protein binding. Generally, plasma proteins tend to 
exhibit strong interactions with free drugs, especially those of hydrophobic nature, once they 
enter the blood circulation. In the case of nanoparticles, the different particle sizes and surface 
properties will have a significant impact on the extent of protein adsorption. As described by the 
Vroman effect, plasma proteins are competitive for a finite number of surface binding sites. The 
process of plasma protein adsorption and dissociation with nanoparticles are kinetic in nature. In 
this regard, varying incubation times will result in different adsorption profiles [210]. In this 
chapter, to investigate the effect of incubation time on the extent of protein adsorption, different 
time points were explored.  
The overall goal of this chapter is to describe studies undertaken to investigate the 
penetration and distribution of CSIC nanocrystals by evaluating mucin-nanocrystal interactions, 
nanocrystal associated plasma protein absorption, drug permeation in human cervicovaginal 
tissues, and pharmacokinetics in a mouse model. As CSIC nanocrystals possessed the 
physicochemical properties desirable for mucus penetration, and nanocrystal formulations in 
general show enhanced tissue permeation, we expected to observe limited interaction between 
mucin and the CSIC nanocrystals, and an increased drug concentration in the cervicovaginal 
tissue compared with CSIC free drug. Genital lymph node drug targeting after nanocrystal 
treatment was therefore be anticipated.  
 
 127 
5.2 MATERIALS AND METHODS 
5.2.1 Materials 
Bovine serum albumin (BSA) was purchased from Spectrum. Dulbecco’s Modification of 
Eagle’s Medium (DMEM) was obtained from Corning. Normal human plasma containing the 
anticoagulant citrate phosphate dextrose was obtained from Lee Biosolutions, Inc. Other 
chemical and reagents were of analytic grade or equivalent. 
 
5.2.2 Methods 
5.2.2.1 Nanocrystal-mucin interaction 
Vaginal fluid simulant (VFS) was prepared as described above (section 4.2.2.3). 
Modified VFS was prepared by adding mucin at a final concentration of 1.5% (w/v), namely 
VFS/mucin [228, 229]. The pH of VFS and VFS/mucin solution were adjusted to either 7 or 4.2 
by adding 0.1N HCl or NaOH. Nanosuspension (reconstituted CSIC nanocrystals) was then 
mixed with VFS/mucin solution (pH 7 or pH 4.2) at a ratio of 10:1. Similar samples were 
prepared in VFS at different pH values and compared as controls. Samples were then 
equilibrated in a 37°C water bath for 2h before particle size analysis. The particle sizes were 
determined by dynamic light scattering using a Malvern Zetasizer Nano ZS.  
 
 128 
5.2.2.2 Plasma protein adsorption 
In the current study, the total amount of protein adsorbed on the surface of free drug or 
CSIC nanocrystals was quantified by BCA protein assay. This method is highly sensitive and 
compatible with typical concentrations of most ionic and nonionic detergents. More importantly, 
the BCA assay is more accurate than the previously applied CBQCA assay because the color 
development reaction involved in the BCA assay for protein quantification does not require the 
detachment of the adsorbed proteins from CSIC nanocrystals [230].  
To investigate the extent of protein adsorption, nanosuspension was mixed with the same 
volume of human plasma and incubated in a 37˚C water bath for either 5 minutes or 1h. Previous 
studies have shown that if nanoparticles can be recognized as foreign, they will be transported to 
the liver and spleen 5 minutes after systemic exposure [231]. Otherwise, these nanoparticles will 
show a prolonged circulation or time-dependent distribution in the body. Therefore, 5 minutes 
time point was selected as a standard and 1h was chosen as a representative extended time point. 
In addition, the sample-to-plasma ratio between drug and human plasma was optimized in 
preliminary studies in order to: (1) minimize the effect of lipids in human plasma on protein 
quantification, and (2) make sure that plasma proteins are in excess of the available nanoparticle 
surface area [230].  
In detail, after incubation, samples were centrifuged at 15,000g for 30 minutes at 25˚C to 
separate CSIC nanocrystal from the majority of unbound plasma proteins. Afterwards, the 
sedimentary drug nanocrystal pellet was washed to remove the rest of the unbound proteins by 
three rounds of centrifugation (15,000g for 30 minutes at 25˚C) and resuspension in PBS 
containing 0.1 % v/v Triton X-100. In this washing step, a mild non-ionic detergent Triton X-100 
was employed since CSIC nanocrystal-protein corona pellets cannot be re-suspended efficiently 
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in the standard washing solution PBS. The use of 0.1% w/v Triton X-100 was comparable to 
other washing solution such as 0.05%  v/v Tween 20 [209]. It should not solubilize the bound 
plasma proteins. Preliminary study conducted in our laboratory also confirmed its limited impact 
on dissolving plasma proteins by quantifying the extent of protein binding with or without 
washing. More importantly, Triton X-100 at this concentration was found to be compatible with 
BCA assay (<5%). Its application would not affect protein quantification.  
After washing, the residue pellets were then dispersed in 0.1 mL 0.1 % Triton X-100 and 
mixed with 2 mL working solutions prepared according to the Pierce BCA Protein assay 
protocol. The adsorbed protein reduced the copper (Cu
2+
) in working solution to cuprous cation 
(Cu
1+
) and the change was detected by BCA in solution. The amount of protein in each solution 
was quantified by UV-spectrophotometer at 562nm.  
In comparison, to quantify the amount of protein adsorbed on the surface of free drug, all 
the procedures remained the same except the washing step. PBS was applied to wash off the 
unbound plasma proteins since the free drug pellet was easily re-dispersible. 
 
5.2.2.3 Tissue permeability study 
Excised human cervical tissues were obtained from the University of Pittsburgh Health 
Sciences Tissue Bank (Pittsburgh, PA) and the protocol was approved by University of 
Pittsburgh IRB #PRO09110431. Tissue samples were collected from healthy volunteers who 
were undergoing hysterectomy. Before the experiments, excess stromal tissue was removed to 
achieve a full thickness of epithelial layer. Tissues were set up in PermeGear In-Line Cells (7mm 
in diameter). Briefly, epithelial tissue was placed horizontally between the donor and receptor 
compartments with the epithelial side facing up. DMEM containing 1% BSA was used as the 
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receptor medium. The receptor medium was pumped through the receptor compartment via a 
coupled peristaltic pump at a rate of 50 μl/min. A fraction collector was used to collect samples 
from the receptor compartment. The whole system was warmed at 37˚C to mimic biological 
conditions.  
To increase the sensitivity of drug quantification, carbon-14 labelled (
14
C) CSIC was 
spiked with regular CSIC. The drug mixture was then used to prepare radiolabeled drug 
nanocrystal and free drug samples. Free drug was uniformly suspended in DMEM containing 
0.1% DMSO. 
0.5ml of CSIC nanosuspension or CSIC free drug at a concentration of 800 μg/mL was 
loaded in each donor chamber respectively. At the end of the 8h experiment, tissues were 
removed from the in-line cells, and each one was cut into three pieces. One piece was sectioned 
consecutively using a cryostat into 100μm sections, and the amount of CSIC retained in each 
section was determined by liquid scintillation counter (LSC) (Beckman LS 6500 Multi-Purpose 
Scintillation Counter). One piece was digested directly for drug content analysis. The last piece 
was stained by Hematoxylin & Eosin (H&E) staining for histological evaluation of tissue 
morphology.  
The flux (J) and the apparent permeability coefficient (Papp) of both CSIC nanocrystal 
and free drug were calculated based on the Fick’s First Law of Diffusion, with the equations 
described below: 
 J=                                                                                                   (Equation 5) 
Papp=                                                                                         (Equation 6) 
 131 
Where, in Equation 5, M is the accumulated amount of drug collected in the receptor 
medium (counts per minute, cpm), A is the area of contact (cm
2
), t is the time of exposure (min), 
dM/dt represents the slope of the curve of M versus t, and the units for J are cpm/(cm
2
*min). In 
the Equation 6, Cd is the initial dosing concentration, and the units for Papp are cm/sec. 
 
5.2.2.4 In vivo drug distribution and genital lymph node drug delivery  
All procedures used in the mouse drug distribution studies were approved by the 
University of Pittsburgh Institutional Animal Care and Use Committee (IACUC) (approval 
number 14114443). In general, 6 week old female Swiss Webster mice were purchased from 
Charles River Inc. Medroxyprogesterone (Depo-Provera) (3mg/animal, 60uL) was injected 
subcutaneously 7 days and 3 days prior to drug exposure. This intervention was applied in the 
field of microbicides and vaginal drug to synchronize the mice to the diestrous stage [105]. On 
the day of experiment, mice were first anesthetized in an induction chamber filled with 3% 
isoflurane-oxygen, and then transferred to a nosecone for continuous anesthetization by 1.5% 
isoflurane-oxygen. Radiolabeled free drug or CSIC nanocrystal was suspended in PBS (800 
µg/mL) and then administrated by genital pipetting into the mouse vagina. After drug 
administration to the mice, anesthesia was maintained for one additional minute. Afterwards, the 
mice were removed from the nosecone, and physically restrained in 50 mL conical tubes 
individually for 20 minutes with their hindquarters elevated. These procedures were designed to 
reduce the extent of drug leakage from the mouse vagina. 
At each predetermined time point after drug exposure (0.5, 1, 2, 4, 24, 48 and 72h), blood 
samples were collected from the submandibular vein. After the exsanguination, mice were 
exposed to carbon dioxide and euthanized by cervical dislocation. Vaginal fluid and adherent 
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mucus in the reproductive tract were collected by PBS lavage. Tissues or organs (lumbar lymph 
node, inguinal lymph node, vagina, ectocervix, endocervix, uterus horn, ovary, liver, kidney, and 
spleen) were harvested from each mouse and washed three times in PBS. After drying, all the 
samples were weighed, and digested for drug content using LSC. 
 
5.2.2.5 The effect of Nonxynol-9 (N-9) pre-treatment on lymph node targeting 
Nonxynol-9 (N-9), a well-known permeation enhancer, was applied to evaluate its effect 
on lymph node drug delivery. Similar studies were carried out using the same mouse model 
described in section 5.2.2.4. In detail, 12 h prior to drug exposure, 30 μl 1% N-9 were instilled 
intravaginally using the same approach as the test articles. Mice were then sacrificed 4h or 24h 
after drug exposure. Inguinal and lumbar nodes were collected for drug content analysis using 
LSC.   
 
5.2.2.6 Statistical analyses 
All results were presented as the mean ± standard deviation (SD). Pairwise differences 
were determined by Student’s t test. P <0.05 was considered as denoting significance unless 
otherwise stated. Two-way ANOVA with Bonferroni test was applied for in vivo 
pharmacokinetic study since two independent variables time and treatment were involved 
(GraphPad Prism 5).  
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5.3 RESULTS 
5.3.1 Nanocrystal-mucin interaction  
In this study, particle sizes of the nanocrystals under different equilibration conditions were 
determined. By comparing the sizes of the nanocrystals in the VFS and the corresponding 
VFS/mucin at the same pH, the potential mucin-nanocrystal interaction could be estimated [228]. 
At pH 4.2, the size of nanocrystals in VFS and VFS/mucin were found to be 256±36 nm and 
282±14nm respectively. No significant difference was observed, indicating a limited mucin-
nanocrystal interaction. Similar results were obtained at pH 7.4, and particle sizes were 
determined to be 266 ±31nm in VFS and 302 ±17nm in VFS/mucin.  
 
5.3.2 Plasma protein adsorption 
In this study, tested articles were incubated with human plasma for a certain period of time, and 
the total amounts of plasma protein adsorbed were quantified. After 5 minutes incubation, 429 
±40 µg/mL plasma proteins were adsorbed on the surface of the nanocrystals. In comparison, 
769 ±164 µg/mL proteins absorbed on the surface of free drug particles. The 1 hour incubation 
gave similar findings: the protein concentrations in the nanocrystal treated and free drug treated 
samples were calculated to be 408 ±86 µg/mL and 639 ±38 µg/mL, respectively. In both 
scenarios, plasma proteins seem to have more interactions with free drug particles than CSIC 
nanocrystals.  
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5.3.3 Tissue permeability study  
5.3.3.1 Flux (J) and apparent permeability coefficient (Papp).  
As CSIC could be detected in the collected receptor medium all through the experiment 
for both CSIC nanocrystals and the free drug, their fluxes and the apparent permeability 
coefficients (Papp) were calculated based on the equations described in the methods section 
(Equation 5 and 6). The resulting data suggested no significant difference between the CSIC 
nanocrystal and free drug for both parameters. The flux of CSIC nanocrystals and the free drug 
were determined to be 7.3 ±5.2 and 6.6 ±3.4 cpm/(cm
2
*sec) respectively (p=0.80). The Papp of 
drug nanocrystals was determined to be 3.2 ±2.3 X10
-7
 cm/sec as compared to 3.0 ±1.5 X10
-7
 
cm/sec for the free drug (p=0.87). 
 
5.3.3.2 Drug permeation in tissue 
The purpose of this study was to investigate mucosal permeation properties of CSIC in 
nanocrystal formulation. Drug contents in the donor chamber (Dend), tissue wash solution, 
receptor chamber (Rend), explant tissue, and the collected receptor medium (cumulative 
collection) were analyzed and presented as percentages in the Table 6. Mass balance was also 
calculated by summing up drug contents in each compartment. As expected, the distribution of 
CSIC nanocrystals was significantly different from that of the free drug.  In terms of mass 
balance, all the dosed CSIC nanocrystals could be recovered (97.4 ±3.84%), whereas only 77.4 
±7.99% of free drug could be collected. More CSIC nanocrystals remained in the donor chamber 
than the free drug (95.1 ±4.25% vs 67.0 ±7.06%). In contrast, substantially higher amounts of 
free drug were found in the tissues, tissue wash solutions, and the receptor chambers than the 
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CSIC nanocrystals. Specifically, in the tissues, drug concentrations for free drug and 
nanocrystals were calculated to be 281.3 ±71.1and 127.8 ±30.0 ug/g of tissue, respectively. In 
addition, the drug contents detected in the cumulative collections were found to be similar 
between these two test articles. This finding was consistent with the calculated flux and Papp.  
 
 
 
Table 6 Drug distribution after an 8h permeability study using explanted human cervicovaginal 
tissues.  
Dend: drug remained in the donor chamber in the in-line cell; Tissue wash: drug detected in the 
tissue wash solution; Rend: drug remained in the receptor chamber in the in-line cell. Tissue: drug 
contents determined in the cervicovaginal tissue. Cumulative collection: the amount of drug in the 
collected receptor medium. All the data are presented as mean±SD. ** indicated p<0.005. n≥5 
 
 
Treatment 
DEnd, % 
** 
Tissue 
REnd, %
** 
Tissue, %** 
Cumulative  Mass  
  Wash, %** Collection,% Balance,% ** 
Nanocrystal 95.1±4.25 0.2±0.06 0.1±0.03 1.3±0.18 0.7±0.51 97.4±3.84 
Free drug  67.0±7.06 5.4±2.58 0.4±0.16 4.0±1.05 0.7±0.33 77.4±7.99 
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Furthermore, to better understand the drug permeation profile, drug content in each tissue 
section from apical epithelium to basal stroma was quantitatively analyzed using LSC (Figure 
27). It is evident that, for both CSIC nanocrystals and the free drug, the amounts of drug were 
highest in the topical 200μm-thick tissues which were mainly the epithelial cells, and gradually 
decreased in the underlying tissue sections. Similar trends were observed for both test articles, 
but much higher amounts were detected in the first 7 layers of tissue sections from the apical side 
after free drug exposure.   
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Figure 27 Drug content in per 100μm section of human ectocervical tissue from the apical 
epithelium to the stroma after 8 hour exposure.  
For both test articles, drug contents in the tissue sections decreased from the superficial epithelium 
to basal layer stroma. Free drug substance was mainly accumulated in the epithelium (the top 
layers of tissue sections).  Data is presented as mean ± SD. 
 
 
 
5.3.3.3 Safety evaluation  
In addition to the permeation study, a safety study was conducted to determine if test 
articles were safe for the epithelium in the female reproductive tract. CSIC nanocrystals or free 
drug in DMSO solution were exposed to human ectocervical tissue using an in-line cell system. 
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After 8h treatment, tissues were removed and stained for histological evaluation. H&E stained 
tissue sections were presented in Figure 28. No gross changes in morphology were observed for 
the tissues exposed to CSIC nanocrystals or free drug when compared to the pre-exposure tissue.  
 
 
 
(a)                                            (b)                                             (c)              
               
 
 
Figure 28 Representative H& E stained epithelium of human cervicovaginal tissue.   
Representative histology pictures of (a) pre-exposure tissue, (b) tissue exposed to CSIC nanocrystals 
for 8h, and (c) tissue exposed to CSIC free drug for 8h. Nuclei of cells were colored by hematoxylin  
and presented in dark blue dots. Eosin was used to stain the cytoplasm in pink. The epithelia of the 
tissues were found to be intact, and the integrity of the tissue could be preserved after CSIC 
nanocrystals or free drug treatment. Micrographs were taken with a 20X objective. (n≥5) 
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5.3.4 In vivo pharmacokinetics and lymph node drug delivery 
The goal of this study was to confirm that nanocrystal formulation can improve tissue 
penetration and, more importantly, deliver drug to genital lymph nodes, which would provide 
protection against HIV-1 transmission through multiple targets.  
 
5.3.4.1 Drug distribution in the reproductive tract 
After intravaginal administration of CSIC nanocrystal or CSIC API to mice, drug 
substances could be detected throughout the reproductive tract and presented a gradient pattern 
from the site of administration to the ovaries. Drug concentration in the tissue peaked at the 
earliest time point (0.5 h) and rapidly decreased afterwards. At 0.5h, nearly 7.3% and 1.2% of 
administrated nanocrystals were detected in the vagina and ectocervix, corresponding to 52% 
and 8.4% of the total amount recovered. As expected, substantially higher amounts of CSIC 
nanocrystals penetrated into the reproductive tract in contrast to the free drug, especially in the 
vaginal and ectocervical tissue (Figure 29). At 0.5h, drug contents in the mouse vagina for CSIC 
nanocrystals and free drug were found to be 23.8 ±6.64 µg/g and 2.2 ±1.46 µg/g respectively. In 
the ectocervix, 8.3±5.81 µg/g CSIC was detected 0.5h after nanocrystal treatment and 0.36 ±0.38 
µg/g after free drug treatment. In addition, more CSIC nanocrystals were found in the uterine 
horn than free drug at 1h and in the ovaries at 0.5h.  
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Figure 29 Drug distribution in the female reproductive tract in mice following intravaginal 
administration of CSIC nanocrystals (NC) or the free drug in PBS (FD).   
Drug substance could be detected throughout the reproductive tract and presented a gradient 
pattern from the site of administration vagina to the ovaries after CSIC nanocrystals or free drug 
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treatment. Higher amounts of CSIC nanocrystals were detected in the vagina at 0.5h, ectocervix at 
0.5h, uterus in the first 1h, and ovary at 0.5h. Note the different scales and units in y-axes, including 
the log-scale for vaginal and ectocervical tissue. Two-way ANOVA with Bonferroni test was applied 
for statistical analysis. * and *** denote significant difference with p<0.05 and p <0.001 respectively 
between CSIC nanocrystals and free drug treatment.  (n=3) 
 
 
 
5.3.4.2 Drug in the vaginal lavage 
The amount of drug remaining in the vaginal lumen is estimated through assessment of 
the drug content in the collected vaginal lavage. By 0.5h, drug concentration in the lavage for 
CSIC nanocrystal treatment group was about 7.3 ± 11.3 µg/mL. Drug contents then rapidly 
decreased to 0.81 ± 0.5 µg/mL and 0.04 ± 0.02 µg/mL after 1h and 4h respectively (Figure 30). 
In comparison, even though there was no significant difference observed between CSIC 
nanocrystal treatment and free drug treatment. The free drug particles seemed to remain longer in 
the vaginal lumen. 
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Figure 30 Drug remained in the vaginal lavage after intravaginal administration of CSIC 
nanocrystals or CSIC free drug. 
No significant difference between these two test articles was observed in terms of drug content 
remained in vaginal lavage. Data is presented in log-scale. Two-way ANOVA with Bonferroni test 
was applied for statistical analysis. No significant difference was observed between CSIC 
nanocrystal and free drug. (n=3) 
 
 
 
5.3.4.3 Systemic exposure 
Drug exposure in the plasma and elimination organs, such as liver, kidney, and spleen 
were also determined (Figure 31). The application of CSIC nanocrystals resulted in a greater 
systemic exposure than the free drug. In the plasma, nanocrystal concentration was much higher 
than that of free drug during the first 24h. The peak value for CSIC nanocrystals was observed at 
1h with a plasma concentration of 0.031 ± 0.005 μg/mL. As for liver, kidney and spleen, CSIC 
nanocrystals migrated to these elimination organs in a much faster mode with higher amounts of 
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drug exposure. The peak nanocrystal concentration was observed at 1h, while the peak 
concentration for CSIC free drug was detected at 24h. Among these three organs, drug exposure 
in the liver for both test articles was found to be higher at all times than that in the kidney, 
followed by the spleen, which might indicate a liver-mediated elimination. Moreover, the higher 
mount of drug exposure detected in spleen after nanocrystal treatment can be an indication for 
lymph node targeting since spleen is a primary lymphoid organ [232].  
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Figure 31 Systemic exposure to CSIC following vaginal administration of CSIC nanocrystals or the 
free drug. 
For both CSIC nanocrystal and free drug treatment, drug substance could be detected in the blood 
and the elimination organs at the earliest time point (0.5h). Compared with CSIC free drug, higher 
amounts of CSIC nanocrystals were detected at 0.5, 1, and 24h in the blood, first 4h in the liver and 
kidney, and the first 1h in the spleen. Drug concentrations in the liver were found to be higher than 
that in the kidney and spleen which might indicate a liver-mediated clearance. Two-way ANOVA 
with Bonferroni test was applied for statistical analysis. *, ** and *** denote significant difference 
when comparing CSIC nanocrystal with free drug at the same time point with p< 0.05, p<0.01, and 
p<0.001. (n=3) 
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5.3.4.4 Lymph node drug delivery 
Drug exposure in the genital lymph nodes was relatively low compared with that in the 
cervicovaginal tissue. No drug could be detected in the inguinal lymph nodes at all the time 
points for both test articles (Figure 32). In comparison, the nanocrystal formation was able to 
deliver antiretroviral drug CSIC to the lumber lymph nodes at 48h (Figure 32). However, as the 
amount of drug detected in the lymph nodes were very low, the quantification method available 
could not conclusively indicate the superiority of CSIC nanocrystals in terms of lymphatic 
targeting. Additionally, the application of permeation enhancer N-9 12h before treatment did not 
enhance lymph node drug delivery of CSIC nanocrystals or free drug at 4h and 24h (Data not 
shown).  
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Figure 32 Drug exposure in lumbar lymph nodes and inguinal lymph nodes over a 72h period of 
time. 
Drug substance was detected in the lumbar lymph nodes 48h after CSIC nanocrystal treatment. No 
CSIC nanocrystals or free drug could be found in the inguinal lymph nodes at any of the time point 
investigated.  A control study using PBS was conducted to indicate the background level. * denotes 
a significant difference (p<0.01) when compared with the PBS control. (n=3) 
 
 
 
5.4 DISCUSSION AND CONCLUSION 
The overall goal of this chapter is to improve drug permeation in the cervicovaginal tissue and 
subsequently deliver drug to the genital lymph nodes after intravaginal instillation using the 
developed CSIC nanocrystal formulation. To achieve this objective, first of all, drug 
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formulations must penetrate through the mucus and be accessible to the female reproductive 
tissue. Previous studies have shown that the test formulations may interact with the mucin in the 
vaginal fluid and this interaction could significantly alter drug retention, release rate, delivery 
kinetics, and bioactivity in the body [233-235]. Therefore, it is important to investigate the 
potential interaction between CSIC nanocrystal and mucin from the perspective of formulation 
development. Based on the data generated in this chapter, CSIC nanocrystals did not seem to 
interact with mucin molecules, since the particle size of the CSIC nanocrystal remained 
unchanged after mucin treatment at both pH 4.2 and 7.0. As the interactions between mucin and 
drug particles are generally induced by hydrophobic and electrostatic forces, these findings 
suggested a complete coverage of the hydrophobic nanocrystal surface by stabilizer HPMC and 
Pluronic 98. Additionally, the minimal negative surface charge (-7.8mV) of CSIC nanocrystals 
might further inhibit their interaction with the negatively charged mucin via electrical repulsion. 
It was worth noting that, however, as the CSIC nanocrystal-mucin mixtures were diluted before 
particle size analysis, even if there was an interaction, it might not be recorded as a size increase.   
It was also found that the mucin-nanocrystal interaction at higher pH (pH 7.0) was 
similar to that at pH4.2. This result was inconsistent with a previous study which showed a lower 
interaction between DPV nanoparticles and mucin at pH 7.0 compared to pH 4.2 [228]. This 
disparity could be a result of different surface charges for CSIC nanocrystals and DPV 
nanoparticles. As for the DPV nanoparticle, the intensity of its surface charge was > -30mV, 
which was much higher than that of CSIC nanocrystals (near neutral, <-10mV). Thus, when the 
ionization of mucin would increase at a higher pH (pH 7.0), meaning it would become more 
negatively charged, and its interaction with the highly negatively charged DPV nanoparticles 
would be further decreased due to the larger electrical repulsion.   
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In addition to the mucus penetration properties, the extents of protein adsorption at two 
different time points were also determined. The resulting data showed that the protein 
concentration after 1 hour of incubation was similar to that after 5 minutes incubation. In 
addition, the extent of protein adsorption on the surface of CSIC nanocrystals was much less than 
that on the free drug particles for both incubation times. This phenomenon could be explained by 
the utilization of Pluronic F98 (a PEG containing polymer) in the nanocrystal formulation, which 
decreased the overall hydrophobicity of the product. This finding is in accordance with previous 
studies showing that PEG could be applied to suppress protein adsorption by blocking the protein 
binding site on the surface of nanoparticles and creating a thermodynamic barrier to protein 
diffusion [236, 237]. Chan and his colleague also reported that increasing PEG grafting density 
on the surface of nanoparticles significantly reduced the extent of protein adsorption and 
changed the composition of the adsorbed proteins when compared to the un-grafted nanoparticles 
[209]. The variation in protein adsorption led to different mechanisms and efficiency of 
nanoparticle uptake by macrophages in the blood. It is worth noting that, as the identities of the 
adsorbed proteins in each sample remained unknown in our scenario, no significant conclusions 
can be drawn at this stage for CSIC nanocrystals or CSIC free drug regarding to their 
macrophage uptake in blood and subsequent biodistribution in vivo.  
To verify the advantage of nanocrystal formulation in terms of tissue penetration, the next 
step was to evaluate drug permeation properties using excised human ectocervical tissue. The 
results have shown that both CSIC free drug and nanocrystals were able to penetrate though the 
cervicovaginal tissues. The flux (J) and the Papp were found to be similar between these two test 
articles. This result is in agreement with another permeability study, which investigated the 
permeation properties of free drug DPV and DPV encapsulated polymeric nanoparticles using 
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pig vaginal mucosa [40]. The Papp of free drug DPV was calculated to be 1.75 ±0.17 cm·s
-1
x10
-6
, 
which was of a similar magnitude but slightly higher than the Papp of the CSIC free drug (3.0 
±1.5cm·s
-1
x10
-7
). Strikingly, the Papp of DPV free drug was found to be lower than that of the 
positively charged DPV nanoparticles, but higher than that of the negatively charged DPV 
nanoparticles. Thus, surface charge seems to play a critical role in determining the Papp.  In our 
scenario, CSIC nanocrystals have a near-neutral charge which is similar to that of the free drug 
molecules. This similarity in surface charge could contribute to the comparable Papp values 
between the CSIC free drug and CSIC nanocrystals.  
In terms of the amount of drug retained in the tissue, drug concentrations determined 
after nanocrystal exposure were found to be significantly lower than the free drug treatment, 
which is not unexpected. This difference could be explained by the precipitation and 
accumulation of free drug on the surface of the tissue. The drug accumulation could significantly 
increase the concentration gradient in the apical layers of epithelium, which facilitated drug 
permeation. In contrast, CSIC nanocrystals were well stabilized and homogenously suspended in 
the solution (95.1 ±4.25%) with a very small fraction of the nanocrystals (0.2 ±0.06%) in contact 
with the tissue. This hypothesis can also be confirmed by the amount of drug detected in the 
most superficial 100 μm-thick tissue: the amounts of free drug were found to be 1309.5 ±341.8 
ng, 2-3 times higher than that after nanocrystal treatment (459 ±212.5 ng).  
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The low drug nanocrystal concentration in the tissue could also be attributed to its 
sustained drug release profile [48]. As drug molecules have to be released first to be absorbed 
and CSIC is released from the nanocrystals in a controlled manner, the concentration of soluble 
drug that is free to be absorbed could be low. In contrast, in the case of CSIC free drug, the 
concentration of soluble drug could be relatively higher due to the presence of the solubilizing 
agent DMSO.  
Along with the differing extents of drug penetration, these two test articles showed 
distinct drug penetration efficiency. Very encouraging, CSIC nanocrystals seem to penetrate 
throughout the tissue more efficiently than the free drug. By comparing the amounts of CSIC 
remaining in the first and last piece of tissue section from the apical epithelium to the basal layer 
stroma, it was determined that over 17% of the CSIC nanocrystal was able to migrate to the 
stroma side, however, only 5% of free drug penetrated through the tissue and located in the 
bottom layers.  
In light of these findings, it was assumed that the impact of the free drug accumulation on 
tissue exposure could be compromised if a reduced dosing level and a shorter period of 
incubation time could be applied. To test this hypothesis, extended study was conducted using 
0.1ml test articles and 0.5h incubation time. As expected, no difference was observed between 
the two test articles in terms of the total amounts of drug remaining in the tissue and the 
cumulative amount of drug collected in the receptor chamber.  
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Notably, in the ex vivo drug permeation study, cervicovaginal mucus was not involved in 
the experimental setup, and the effect of tissue permeation on lymphatic drug delivery could not 
be investigated. Therefore, it is worthwhile to explore the permeation properties in vivo using an 
animal model and verify drug exposure in the genital lymph nodes. The animal study performed 
in this chapter is the first pharmacokinetic study for the anti-retroviral drug CSIC.  
The resulting data has shown that CSIC nanocrystals presented mainly in the vagina and 
ectocervix, and to some extent in the uterus and ovaries. Drug exposure in the entire FRT was 
favorable since the upper FRT might also contribute to viral transmission [9]. The existence of 
drug in the ovary, despite it only accounted for 0.01% of the dosed drug, was consistent with a 
previous study conducted by Hope’s group. They found that SIV-based dual reporter particles 
could reached macaque ovaries 48h after vaginal inoculation [70]. Other studies investigating 
drug distribution of PLGA nanoparticles and Qdots in mouse FRT did not report the presence of 
drug in the ovaries [105, 238]. The disparity between different investigations could be attributed 
to the following reasons. First of all, to prevent drug leakage, the mice in current study were 
physical restrained in cornicle tubes with their hindquarters elevated for 20 minutes after drug 
instillation. This body position might induce the formulations to migrate down to the ovaries. In 
addition, first-uterine-pass effect might play a role in the transfer of vaginally administered 
hydrophobic drugs to the uterus/ovary. Evidence of this effect can be confirmed by other drugs 
such as progesterone, terbutaline, and danazol [23]. In the case of the CSIC nanocrystal 
formulation, the pure drug particles were stabilized by the stabilizers but not encapsulated in 
surface modified nanocarrrier systems. Therefore, the hydrophobic property of CSIC was 
somehow reserved and induced the first-uterine-pass effect. Furthermore, the limited mucin-
nanocrystal interactions described earlier might also facilitate the wide distribution of 
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nanocrystals within the whole reproductive tract. Lastly, the quantification method applied in the 
present work (LSC) was more sensitive than measuring the intensity of fluorescent signals so 
that extremely low amounts of drug exposure could be detected. 
To better understand the elimination rate of CSIC nanocrystals in the reproductive tract, 
the total amount of drug remaining in the vaginal lavage and the genital tissue at various time 
points were determined. As early as 0.5h, over 85% of the loaded nanocrystals had already been 
cleared. The amount of drug detected at 1h had further decreased to 2%. After 24h, only a trace 
amount of drug could be quantified. The clearance rate of CSIC nanocrystals was found to be 
similar but faster than other nanoparticles [238, 239]. Previous studies have shown that over 30% 
surface modified PLGA nanoparticles and rhodamine-loaded poly(epsilon-caprolactone) (PCL) 
nanoparticles could be recovered after 0.5h administration, and about 10% detected by 2h. In our 
case, other than vaginal leakage, another plausible explanation for the fast drug loss could be the 
stress induced by physical restraints. The stress might increase the frequency of urination and the 
bowel activity, which in turn accelerated the elimination of the administered drug.  
Compared with the CSIC nanocrystals, the residence of free drug in the vagina and 
ectocervix were one order of magnitude lower, especially at earlier time points (Figure 29). This 
result was in line with the biodistribution of free dapivirine (DPV, another tight binding NNRTI 
as CSIC), which presented a lower tissue exposure in the vagina and lower uterus compared to 
the corresponding DPV-loaded nanoparticles [239]. More importantly, a previous study by 
Ensign et al. has demonstrated that mucus penetrating PEG-coated nanoparticles could provide 
more protection against Herpes Simplex virus after intravaginal administration than the soluble 
drug. This increased protection from nanoparticles was attributed to the more uniform drug 
distribution on the vaginal epithelial and rapid penetration into rugae with more drug retained in 
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the tissue [240]. This finding thus suggests that the increased CSIC concentration in the tissue 
after CSIC nanocrystal treatment is beneficial and would lead to a better protection against HIV 
transmission in the female reproductive tract. In addition, Ensign et al. further showed that the 
application in a hypotonic medium enhanced drug uptake due to a more uniform and intimate 
contact with the vaginal surface. In future work, it would be interesting to see whether their 
method would result in a still greater drug uptake from our nanoparticles [241].  
The amounts of drug present in the vaginal lavage after CSIC nanocrystals or free drug 
administration were also analyzed (Figure 30). Unexpectedly, the difference between the two 
treatments was not statistically significant. Only at 4h, drug concentrations obtained in the free 
drug treated mice were found to be slightly higher than the nanocrystal treated ones. This result 
could be explained by their different mucus penetrating properties. Considering that CSIC is very 
hydrophobic, it was likely that mucin proteins entangled with the free drug aggregates and 
hindered their migration to the cervicovaginal tissues. In contrast, CSIC nanocrystals, as a type 
of mucus-penetrating nanoparticle, penetrated through the mucus rapidly and eventually enter the 
vaginal folds [240].  
In addition, drug concentrations in the plasma and elimination organs were evaluated as 
criteria of systemic exposure (Figure 31). It was found that drug contents in plasma after both 
treatments were extremely low. At 0.5h, plasmatic level of CSIC nanocrystal was only about 
0.02 µg/mL corresponding to 0.03% of initial dose, which was much lower than the DPV free 
dug (0.099 µg/g, 3%) and DPV nanoparticles (0.026 µg/g, 0.8%) at 15 minutes  after vaginal 
administration [239]. As for drug exposure in the liver and kidney, CSIC concentrations for both 
formulations were determined to be relatively higher than DPV nanoparticles, but still at very 
low levels. Drug concentrations detected in the plasma were found to be very low compared with 
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the amount of drug remained in the cervicovaginal tissue. This result is desirable since the 
limited systemic drug exposure can curb the progress of drug resistance, especially for non-
nucleoside reverse transcriptase inhibitors (NNRTIs). NNRTIs have the longest half-life in 
plasma compared with other classes of antiretroviral drug [242, 243]. When the drug 
concentration in plasma reaches to a threshold, there is an increased risk of developing drug 
resistance. More importantly, NNRTIs have a low genetic barrier to the viral mutants selected 
from other within-class drugs. Therefore, existing NNRTI resistance could potentially 
compromise the efficacy of future regimens that containing other NNRTIs. Accordingly, it is 
critical to monitor NNRIT plasma concentration and maintain a low systemic concentration. For 
drug CSIC, however, there is no information available about its resistance threshold. Therefore, 
we have to use the threshold determined for nevirapine (0.25µg/mL) [244], which is another 
NNRTI with a similar half-life compared to CSIC. It was found that CSIC plasma concentration 
(0.02µg/mL) was much lower than this threshold and should not induce drug resistance. 
In the current animal study, we were also interested in drug transport in the genital lymph 
nodes. Very encouragingly, without N-9 pretreatment, CSIC could be detected in the lumbar 
nodes 48h after nanocrystal administration, whereas neither of the two test articles was observed 
in the inguinal lymph nodes at any of the time points. Similarly, a previous study investigated the 
lymphatic transport of Qdots from vaginal lumen to draining lymph nodes after N-9 
pretreatment. This study showed the drainage of Qdots to both the inguinal lymph nodes and the 
lumbar lymph, with peak concentrations observed at 36 hr [105]. In comparison, the lymphatic 
trafficking of CSIC nanocrystal was found to be slower than that for Qdots, which could be 
explained by the much larger particle size of the nanocrystals and the tissue damage caused by 
N-9 intervention in the Qdots study.  
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To understand the mechanism of lymph node drug targeting, another set of studies were 
carried out using the same mouse model, while mouse vagina were pretreated with the 
permeation enhance N-9 intravaginally. Unexpectedly, N-9 treatment 12h prior to drug exposure 
did not enhance the lymph node drug delivery for CSIC nanocrystals. This observation differed 
from the Qdots study which reported an enhanced transport of Qdots to lumbar lymph nodes by 
prior vaginal installation of N-9 [105]. As the driving force of Qdots migration was the secretion 
of inflammatory cytokines, the mechanism behind for CSIC nanocrystals should not be the same 
[245]. Another possible interpretation is the solubilization effect of N-9 on drug. If both CSIC 
nanocrystals and CSIC free drug were dissolved in N-9, no difference will be expected between 
these two treatments. Last but not the least, considering that the amounts of drug detected in the 
nodes were extremely low, the effect of N-9 on nanocrystal lymph node delivery cannot be 
determined due to the limitation of the current techniques.  
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Another limitation of this study is that there is no direct or indict evidence to confirm the 
presence of the intact nanocrystals in the draining lymph nodes. In another word, CSIC 
molecules might be released from the nanocrystals on the way of migration and existed as free 
drug substance in the lymph nodes. To answer this question, one possible approach is to 
administrate free drug intravaginally and determine the amount of drug exposure in the nodes. 
As free drug solution can be easily leaked out from the vagina, alternative formulation such as 
CSIC containing vaginal film will be applied to control the actual dosing level. In this case, if no 
drug or less amount of drug is detected in the lymph nodes after CSIC vaginal films intervention, 
then it can be concluded that CSIC nanocrystals can make it to the lymph nodes or at least 
facilitate the lymphatic draining of the hydrophobic drug CSIC. Collectively, these control 
studies would demonstrate enhanced drug exposure in the lymph nodes by nanocrystal 
instillation is not simply due to the higher local concentration achieved. 
In conclusion, CSIC nanocrystals act as mucus penetrating nanoparticles presenting 
limited interactions with mucin. Formulating free CSIC into nanocrystals did not improve the 
drug permeation in the explanted cervicovaginal tissue due to the free drug accumulation and the 
application of a solubilizing agent to prepare free drug suspension. However, enhanced drug 
exposure in the reproductive tract and lumbar lymph nodes were observed in a mouse model.  
CSIC nanocrystals showed limited systemic exposure and a reduced protein adsorption profile 
after intravaginal administration. Overall, CSIC nanocrystals are a promising formulation for the 
purpose of vaginal drug delivery and lymph node targeting.  
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6.0  MAJOR FINDINGS AND FUTURE DIRECTIONS 
6.1  MAJOR FINDINGS AND IMPLICATIONS  
Throughout the last decade, HIV/AIDS remains a major health concern globally. Over half of the 
people living with HIV are women. Due to this high percentage, prevention approaches focused 
on sexual transmission in the female reproductive tract, such as vaginal microbicides, are in 
development. The CSIC containing microbicide products developed in this dissertation display 
substantially increased drug solubility, which is a crucial parameter to increase their efficacy. 
Furthermore, this work proved for the first time the possibility of lymphatic targeting after 
intravaginal administration. These improvements will allow a much higher drug dosing level, 
increased drug concentration at the site of viral entry and additional protection in the regional 
lymph nodes. All these factors will lead to an improved anti-HIV efficacy having significant 
contribution to the microbicide field.   
The work conducted in this dissertation was based on the hypotheses that (1) the 
hydrophobic microbicide drug candidate CSIC can be formulated in a polymeric vaginal film 
and a nanocrystal formulation with high loading capacities using multiple solubilization 
strategies; and (2) the nano-delivery strategy can improve cervicovaginal tissue drug penetration 
and achieve lymphatic drug delivery. The studies performed to address these hypotheses 
included preformation study, film formulation development using a co-solvent strategy, rational 
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design of a nanocrystal formulation, drug permeation investigation through excised human 
tissue, and in vivo distribution in the cervicovaginal tissue and genital lymph nodes following 
CSIC nanocrystal instillation. The major findings of the dissertation are summarized below.  
 
6.1.1 Major findings 
6.1.1.1 Preformulation evaluation of CSIC 
The microbicide drug candidate CSIC is practically insoluble in aqueous solutions, with 
an octanol/water partition coefficient (Log Poct/wat) of 3.7. CSIC aqueous solubility was enhanced 
through utilization of a co-solvent system comprised of PEG400, propylene glycol, and glycerin. 
Use of this system resulted in enhancement of aqueous solubility by over 1000 fold. The raw 
crystalline drug substance was found to be extremely stable under various pH, temperature and 
oxidization conditions. The only susceptibility identified for this drug in terms of stability was 
photosensitivity. For this reason, special care should be taken to protect CSIC from light during 
the process of handling, manufacturing, and packaging. The cytotoxic profile of CSIC in the 
epithelial cell line HEC-1A and macrophage-like cell line J774A.1 were determined to be 
concentration dependent with CC50 values around 5 µg/mL. This concentration should provide 
sufficient anti-HIV activity since it is several orders of magnitude higher than the EC50 of CSIC. 
The results generated in the preformulation study were applied subsequently in the formulation 
development and evaluation.  
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6.1.1.2  CSIC containing vaginal film 
A co-solvent system consisting of PEG 400, propylene glycol and glycerin was optimized 
using a ternary phase diagram. The optimized co-solvent system was employed to disperse CSIC 
uniformly in a water-soluble film dosage form. The utilization of these cosolvents not only 
enhanced the solubility of the hydrophobic drug but also improved the flexibility and softness of 
the vaginal film product. More importantly, by optimizing the ratio among the co-solvents, the 
total amount of solvents being used was controlled to avoid any potential side effects such as 
epithelial damage, which may lead to increased risk of HIV infection. The vaginal film 
formulation developed utilizing the co-solvent system for enhanced solubilization of the 
hydrophobic drug CSIC has the potential to be applied as a platform to deliver other hydrophobic 
drugs with a high loading capacity.  In regards to drug release, an initial burst effect was 
observed for CSIC films. This property will allow the development of a coitally dependent 
microbicide product providing a sufficient drug concentration at the site of HIV entry.   
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6.1.1.3 CSIC nanocrystal: preparation and intracellular uptake 
The CSIC nanocrystal formulation was prepared for vaginal administration using a 
nanoprecipitation method. Pluronic F98 and HPMC E5 were chosen in this formulation to 
stabilize the drug nanocrystals and prevent them from crystal aggregation. A particle size of 
243nm and a near neutral surface charge were achieved.  These properties were desired to 
achieve rapid mucus penetration. Different from the film formulation, the CSIC nanocrystals 
feature a controlled and sustained drug release profile lasting for 4 days. This release profile 
indicates its potential application as a coitally independent microbicide product that might 
significantly increase the dosing interval and improve user adherence. CSIC nanocrystals were 
found to be readily internalized by macrophages and get into the cytoplasm via a clathrin 
mediated endocytosis pathway.  
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6.1.1.4 CSIC nanocrystal: drug permeation and lymph node drug delivery 
Limited interactions between CSIC nanocrystal and mucin were found in this study, 
which indicates that the nanocrystal formulation can readily penetrate the mucus present at the 
cervicovaginal epithelium. Because mucus is the major barrier for vaginal drug delivery, the 
mucus penetration property will ensure drug access to the underlying epithelial cells. In addition, 
formulating CSIC into nanocrystals significantly enhanced its permeation efficiency across 
cervicovaginal tissue. When CSIC nanocrystals were topically administrated in the mouse 
vagina, increased drug concentration was detected in the mouse reproductive tissue, especially in 
the vagina and ectocervix, compared with the free drug treatment. The increased drug exposure 
at the site of HIV entry is favorable for increased anti-HIV efficacy. More importantly, results 
showed the presence of drug in the lumber lymph nodes after nanocrystal treatment. This is the 
first study that confirmed the feasibility of lymph node drug targeting after vaginal instillation 
without the use of the permeation enhancer N-9 in the microbicide field.  
 
6.1.2 Contribution to the field of vaginal microbicide 
In this dissertation project, the data generated from the preformation studies provides the most 
critical information required for the development of vaginal products. Therefore, research can be 
extended to other dosage forms, such as vaginal gels, tablets, rings, or other vaginal applied 
nanocarrrier systems.  The existence of multiple dosage forms will provide women with more 
choices, which in turn will improve user adherence. 
Since an increasing number of microbicide drug candidates are hydrophobic in nature, 
the co-solvent strategy presented in this dissertation contributes to the advancement of 
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microbicides by offering a strategy for facilitating formulation development of hydrophobic 
drugs for vaginal delivery. The utilization of this cosolvent strategy will increase drug loading 
capacity substantially while the safety properties required for microbicide products remain 
unaffected.  
It is well known that potential users are more likely to adhere to drug dosing regimens 
which require limited times of product administration [246, 247].  Sustained and controlled 
delivery of a microbicide holds significant potential as a cost-effective strategy for the treatment 
of sexually transmitted HIV-1. This release profile can improve user adherence and maintain a 
therapeutic drug concentration in the vaginal fluid and the cervicovaginal tissue over a long 
period of time. More importantly, controlled release microbicide products can be applied in a 
coitally independent fashion which may enable greater coverage of all sexual contacts, especially 
those that are unanticipated or coerced.  Hence such a regimen may provide better overall 
product effectiveness. Currently, the intravaginal ring (IVR) is the main device being 
investigated for this purpose. However, not all women may choose to use a ring product, more 
options need to be provided to further improve user compliance. In the current dissertation work, 
a CSIC nanocrystal formulation was developed that can release the drug in a sustained and 
controlled manner. Considering that nanocrystals can be incorporated into other dosage forms 
such as hydrogels and polymeric films [248, 249], sustained drug release from traditional vaginal 
dosage forms can be achieved. These products can be applied as promising alternatives to 
vaginal rings. Additionally, as nanocrystal technology is a universal approach to formulate 
hydrophobic drugs, this formulation strategy can be applied as a novel platform for the sustained 
delivery of many other hydrophobic microbicides after vaginal administration.  
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The pharmacokinetic study performed in this dissertation project is the first piece of work 
in the microbicide field investigating drug delivery to both cervicovaginal tissue and genital 
lymph nodes. We were able to prove the possibility of achieving lymph node drug targeting after 
intravaginal instillation without N-9 intervention. Our accomplishment reinforces the importance 
of lymphatic drug delivery. The distribution of microbicides in the genital lymph nodes warrants 
future investigation when considering vaginal instillation.  
 
6.2 FUTURE DIRECTIONS 
Although CSIC nanocrystal formulation is found to be promising as a vaginal microbicide 
product and it has the capacity to deliver drug to both cervicovaginal tissue and lumber lymph 
nodes, a number of studies need to be completed to further evaluate this formulation and 
elucidate the mechanism of lymph node targeting. In addition, as nanocrystals can be formulated 
in a final dosage form, such as vaginal film or gel, further studies are warranted to develop 
formulations for nanocrystals incorporation and delivery. 
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Further evaluation of CSIC Nanocrystal formulation:  
In the current dissertation study, the stability of CSIC nanocrystal was evaluated at room 
temperature in both solid and liquid states. To expand the assessment as per ICH guidelines and 
published literatures [213, 250, 251], nanocrystal product needs be stored at different 
temperature and humidity conditions including 4°C, 25°C/60% RH, 30°C/65% RH and 
40°C/60% RH for 12 months. At various time points, physicochemical parameters such as 
particle size, size distribution, surface charge, crystal morphology, drug content, and in vitro 
release will be evaluated and compared with time zero.  
To translate this formulation to clinical application, the safety profile of CSIC 
nanocrystals must be investigated. First, the nanocrystals need to be incubated with lactobacillus 
cultures to evaluate its effect on lactobacillus colonization. This acute toxicity study can only be 
performed in vitro since no vaginal environment in an animal model has been reported to be 
lactobacillus dominant and acidic [42, 252]. In addition, it is important to investigate the toxic 
effect of CSIC nanocrystal in mouse vagina. The study can be conducted by measuring the levels 
of proinflammatory cytokines, chemokines and granulocyte elastase in the vaginal lavage [253]. 
The selected markers must be able to represent a broad range of inflammatory processes. The 
data collected will provide a good rationale for designing a safe dosing regimen.   
Additionally, it will be very interesting to investigate the memory effect of CSIC 
nanocrystals. Since drug can be released from the nanocrystals in a sustained mode for 96h, we 
expect to see a much longer protection period against HIV acquisition in comparison with CSIC 
containing vaginal film. 
To better visualize the advantage of CSIC nanocrystals for tissue permeation, tissue 
permeability study of CSIC nanocrystals and CSIC free drug need to be conducted using a Side-
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Bi-Side cell system (Figure 33). In contrast to the in-line cell system applied in this dissertation, 
the free drug aggregates will accumulate at the bottom of the donor chamber in the Side-Bi-Side 
cells, thus avoiding direct contact with the cervicovaginal tissue. In this way, the effect of free 
drug accumulation on drug permeation in the tissue can be circumvented.  
 
 
 
 
 
 
Figure 33 Side-Bi-Side Cell 
In the future studies, excised human cervicovaginal tissue will be placed between the donor 
chamber and receptor chamber and displayed horizontally.  
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In the pharmacokinetic study, drug distribution from vagina to ovary has been accurately 
quantified. In the next step, this study needs to be extended to investigate the depth of drug 
penetration from the apical epithelium to stroma. To further investigate drug distribution in 
mouse, the whole female reproductive tract collected will be cut into a reasonable number of 
pieces in sequential orders. Each individual piece of tissue will be fixed and sectioned 
consecutively to 100µm sections as the method described in the human tissue permeability study. 
Drug content in each tissue section will be determined by a liquid scintillation counter. By 
encoding the amounts of drug available together with their in situ position, a three-dimensional 
drug localization profile can be obtained. These results will allow a more comprehensive 
understanding of drug distribution and penetration in the reproductive tissue after vaginal 
administration.    
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Further elucidation of mechanisms: 
The pharmacokinetic study performed in the current dissertation has proved the presence 
of CSIC in the lumbar lymph nodes. To continue this project, it will be very interesting to 
explore the mechanism/pathway associated with the lymphatic trafficking. Previous studies have 
shown that CD4
+
 T cells exist abundantly in the cervicovaginal epithelium, and they normally 
drain to the T cell zone in the lymph nodes [16]. Thus, the uptake of CSIC nanocrystals in CD4
+
 
T cells might contribute to the drug transport in the lumber nodes.  In addition, antigen 
presenting cells such as macrophages and dendritic cells (Langerhans cells) also have the 
capability to uptake and transport antigens/particles to the draining lymph nodes. Therefore, to 
better understand the mechanism/pathway of lymph node drug delivery, it is important to test (1) 
the uptake profile of CSIC nanocrystal in at least CD4
+
 T cells, and dendritic cells (Langerhans 
cells), and (2) isolate each type of cell from mouse reproductive tissue after intravaginal 
administration of CSIC nanocrystals and analysis drug content individually.  
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Further development of dosage form: 
Research on incorporation of CSIC nanocrystal/nanosuspension in a final formulation is 
warranted. The final products could be vaginal films, gels or tablets. This transformation will 
allow the final products for easy application and less leakage. It might also improve drug 
retention in the vaginal lumen and increase drug concentration in the vaginal lavage and 
cervicovaginal tissue. It is worth noting that the stabilizers used in the nanocrystal formulation 
might be incompatible with the new excipients employed in the final dosage form. Therefore, 
drug particle size, crystal properties, dissolution profile, and mucus penetration characteristics 
must be evaluated in the final formulation to ensure desirable tissue penetration and 
biodistribution. 
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